BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60:940-947. [PMID: 24374295 DOI: 10.1016/j.jhep.2013.12.019] [Cited by in Crossref: 495] [Cited by in F6Publishing: 446] [Article Influence: 55.0] [Reference Citation Analysis]
Number Citing Articles
1 Doycheva I, Leise MD, Watt KD. The Intestinal Microbiome and the Liver Transplant Recipient: What We Know and What We Need to Know. Transplantation. 2016;100:61-68. [PMID: 26647107 DOI: 10.1097/tp.0000000000001008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
2 Torres J, Palmela C, Brito H, Bao X, Ruiqi H, Moura-Santos P, Pereira da Silva J, Oliveira A, Vieira C, Perez K, Itzkowitz SH, Colombel JF, Humbert L, Rainteau D, Cravo M, Rodrigues CM, Hu J. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. United European Gastroenterol J. 2018;6:112-122. [PMID: 29435321 DOI: 10.1177/2050640617708953] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
3 Irvine KM, Banh X, Gadd VL, Wojcik KK, Ariffin JK, Jose S, Lukowski S, Baillie GJ, Sweet MJ, Powell EE. CRIg-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites. JCI Insight 2016;1:e86914. [PMID: 27699269 DOI: 10.1172/jci.insight.86914] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
4 Golonka R, Yeoh BS, Vijay-Kumar M. Dietary Additives and Supplements Revisited: The Fewer, the Safer for Liver and Gut Health. Curr Pharmacol Rep 2019;5:303-16. [PMID: 32864300 DOI: 10.1007/s40495-019-00187-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Bhat M, Arendt BM, Bhat V, Renner EL, Humar A, Allard JP. Implication of the intestinal microbiome in complications of cirrhosis. World J Hepatol 2016; 8(27): 1128-1136 [PMID: 27721918 DOI: 10.4254/wjh.v8.i27.1128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
6 Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal Barrier in Human Health and Disease. Int J Environ Res Public Health 2021;18:12836. [PMID: 34886561 DOI: 10.3390/ijerph182312836] [Reference Citation Analysis]
7 Arukha AP, Freguia CF, Mishra M, Jha JK, Kariyawasam S, Fanger NA, Zimmermann EM, Fanger GR, Sahay B. Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire. Biomedicines 2021;9:1098. [PMID: 34572293 DOI: 10.3390/biomedicines9091098] [Reference Citation Analysis]
8 Bajaj JS, Cox IJ, Betrapally NS, Heuman DM, Schubert ML, Ratneswaran M, Hylemon PB, White MB, Daita K, Noble NA, Sikaroodi M, Williams R, Crossey MM, Taylor-Robinson SD, Gillevet PM. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol. 2014;307:G951-G957. [PMID: 25258407 DOI: 10.1152/ajpgi.00268.2014] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 12.8] [Reference Citation Analysis]
9 Rao BC, Lou JM, Wang WJ, Li A, Cui GY, Yu ZJ, Ren ZG. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2020;19:109-15. [PMID: 32037278 DOI: 10.1016/j.hbpd.2020.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Ortigão R, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D. Gastrointestinal Microbiome - What We Need to Know in Clinical Practice. GE Port J Gastroenterol 2020;27:336-51. [PMID: 32999906 DOI: 10.1159/000505036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chou YT, Liu TT, Yang UC, Huang CC, Liu CW, Huang SF, Li TH, Liu HM, Lin MW, Yang YY, Lee TY, Huang YH, Hou MC, Lin HC. Intestinal SIRT1 Deficiency-Related Intestinal Inflammation and Dysbiosis Aggravate TNFα-Mediated Renal Dysfunction in Cirrhotic Ascitic Mice. Int J Mol Sci 2021;22:1233. [PMID: 33513830 DOI: 10.3390/ijms22031233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bernsmeier C, Singanayagam A, Patel VC, Wendon J, Antoniades CG. Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure. Immunotherapy. 2015;7:641-654. [PMID: 26065379 DOI: 10.2217/imt.15.27] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
13 Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50:628-639. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
14 Hatton G, Shawcross DL. Is treating the gut microbiome the key to achieving better outcomes in cirrhosis? Expert Review of Gastroenterology & Hepatology 2018;13:1-2. [DOI: 10.1080/17474124.2019.1543587] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
15 Zhong X, Cui P, Jiang J, Ning C, Liang B, Zhou J, Tian L, Zhang Y, Lei T, Zuo T, Ye L, Huang J, Chen H. Streptococcus, the Predominant Bacterium to Predict the Severity of Liver Injury in Alcoholic Liver Disease. Front Cell Infect Microbiol 2021;11:649060. [PMID: 33816353 DOI: 10.3389/fcimb.2021.649060] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Peña-Rodríguez M, Vega-Magaña N, García-Benavides L, Zepeda-Nuño JS, Gutierrez-Silerio GY, González-Hernández LA, Andrade-Villanueva JF, Del Toro-Arreola S, Pereira-Suárez AL, Bueno-Topete MR. Butyrate administration strengthens the intestinal epithelium and improves intestinal dysbiosis in a cholestasis fibrosis model. J Appl Microbiol 2021. [PMID: 33982373 DOI: 10.1111/jam.15135] [Reference Citation Analysis]
17 Iacob S, Iacob DG. Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis. Front Microbiol 2019;10:1676. [PMID: 31447793 DOI: 10.3389/fmicb.2019.01676] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 14.0] [Reference Citation Analysis]
18 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Hsu CL, Duan Y, Fouts DE, Schnabl B. Intestinal virome and therapeutic potential of bacteriophages in liver disease. J Hepatol 2021:S0168-8278(21)01997-8. [PMID: 34437908 DOI: 10.1016/j.jhep.2021.08.003] [Reference Citation Analysis]
20 Fukui H. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. J Clin Transl Hepatol 2017;5:249-60. [PMID: 28936406 DOI: 10.14218/JCTH.2017.00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
21 Amin A, Mookerjee RP. Acute-on-chronic liver failure: definition, prognosis and management. Frontline Gastroenterol 2020;11:458-67. [PMID: 33101624 DOI: 10.1136/flgastro-2018-101103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Hourigan SK, Moutinho TJ Jr, Berenz A, Papin J, Guha P, Bangiolo L, Oliphant S, Provenzano M, Baveja R, Baker R, Vilboux T, Levy S, Deopujari V, Nataro JP, Niederhuber JE, Moore SR. Gram-negative Microbiota Blooms in Premature Twins Discordant for Parenteral Nutrition-associated Cholestasis. J Pediatr Gastroenterol Nutr 2020;70:640-4. [PMID: 31939866 DOI: 10.1097/MPG.0000000000002617] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Swaminathan M, Ellul MA, Cross TJ. Hepatic encephalopathy: current challenges and future prospects. Hepat Med. 2018;10:1-11. [PMID: 29606895 DOI: 10.2147/hmer.s118964] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 5.8] [Reference Citation Analysis]
24 Gustot T. New findings about an 'old' drug: immunomodulatory effects of norfloxacin in cirrhosis. J Hepatol 2014;61:725-6. [PMID: 24996045 DOI: 10.1016/j.jhep.2014.06.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Sarangi AN, Goel A, Aggarwal R. Methods for Studying Gut Microbiota: A Primer for Physicians. J Clin Exp Hepatol 2019;9:62-73. [PMID: 30774267 DOI: 10.1016/j.jceh.2018.04.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
26 Gui QF, Jin HL, Zhu F, Lu HF, Zhang Q, Xu J, Yang YM, Xiao C. Gut microbiota signatures in Schistosoma japonicum infection-induced liver cirrhosis patients: a case-control study. Infect Dis Poverty 2021;10:43. [PMID: 33771232 DOI: 10.1186/s40249-021-00821-8] [Reference Citation Analysis]
27 Chen Y, Sun J, Fan X, Wang X, Zeng L, Zhang X, Zhang K, Li N, Han Q, Liu Z. Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure. Front Pharmacol 2021;12:648736. [PMID: 33967787 DOI: 10.3389/fphar.2021.648736] [Reference Citation Analysis]
28 Prieto I, Hidalgo M, Segarra AB, Martínez-Rodríguez AM, Cobo A, Ramírez M, Abriouel H, Gálvez A, Martínez-Cañamero M. Influence of a diet enriched with virgin olive oil or butter on mouse gut microbiota and its correlation to physiological and biochemical parameters related to metabolic syndrome. PLoS One 2018;13:e0190368. [PMID: 29293629 DOI: 10.1371/journal.pone.0190368] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
29 Bajaj JS. Gut Microbiota as Biosensors in Patients With Cirrhosis. Cell Mol Gastroenterol Hepatol 2019;8:231-3. [PMID: 31132339 DOI: 10.1016/j.jcmgh.2019.04.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Zhu J, Qi X, Yu H, Yoshida EM, Mendez-Sanchez N, Zhang X, Wang R, Deng H, Li J, Han D, Guo X. Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis. United European Gastroenterol J. 2018;6:1179-1187. [PMID: 30288280 DOI: 10.1177/2050640618773564] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
31 Lu YX, Chang YZ, Liang P, Yang CQ. Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir. Infect Dis Ther 2021;10:1519-30. [PMID: 34132991 DOI: 10.1007/s40121-021-00463-1] [Reference Citation Analysis]
32 Tranah TH, Paolino A, Shawcross DL. Pathophysiological mechanisms of hepatic encephalopathy. Clin Liver Dis (Hoboken) 2015;5:59-63. [PMID: 31040951 DOI: 10.1002/cld.445] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
33 Ahluwalia V, Betrapally NS, Hylemon PB, White MB, Gillevet PM, Unser AB, Fagan A, Daita K, Heuman DM, Zhou H, Sikaroodi M, Bajaj JS. Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis. Sci Rep. 2016;6:26800. [PMID: 27225869 DOI: 10.1038/srep26800] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 15.0] [Reference Citation Analysis]
34 Gleeson MW. Interplay of Liver Disease and Gut Microbiota in the Development of Colorectal Neoplasia. Curr Treat Options Gastro 2019;17:378-93. [DOI: 10.1007/s11938-019-00241-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
35 Doré J, Multon MC, Béhier JM, Affagard H, Andremont A, Barthélémy P, Batista R, Bonneville M, Bonny C, Boyaval G, Chamaillard M, Chevalier MP, Cordaillat-Simmons M, Cournarie F, Diaz I, Guillaume E, Guyard C, Jouvin-Marche E, Martin FP, Petiteau D; les participants à la table ronde 2 des Ateliers de Giens XXXII. Microbiote intestinal : qu’en attendre au plan physiologique et thérapeutique ? Therapie 2017;72:1-19. [PMID: 28214070 DOI: 10.1016/j.therap.2017.01.001] [Reference Citation Analysis]
36 Lu X, Wang F. Lactobacillus acidophilus and vitamin C attenuate ethanol-induced intestinal and liver injury in mice. Exp Ther Med 2021;22:1005. [PMID: 34345287 DOI: 10.3892/etm.2021.10438] [Reference Citation Analysis]
37 Barcena-Varela M, Lujambio A. The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers (Basel) 2021;13:2621. [PMID: 34073538 DOI: 10.3390/cancers13112621] [Reference Citation Analysis]
38 Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 2019; 25(22): 2706-2719 [PMID: 31235994 DOI: 10.3748/wjg.v25.i22.2706] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 42] [Article Influence: 18.3] [Reference Citation Analysis]
39 Weir V, Reddy KR. Nonpharmacologic Management of Hepatic Encephalopathy. Clinics in Liver Disease 2020;24:243-61. [DOI: 10.1016/j.cld.2020.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
40 Bajaj JS, Sterling RK, Betrapally NS, Nixon DE, Fuchs M, Daita K, Heuman DM, Sikaroodi M, Hylemon PB, White MB. HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. Aliment Pharmacol Ther. 2016;44:638-643. [PMID: 27417456 DOI: 10.1111/apt.13732] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
41 Bajaj JS, Ahluwalia V, Steinberg JL, Hobgood S, Boling PA, Godschalk M, Habib S, White MB, Fagan A, Gavis EA, Ganapathy D, Hylemon PB, Stewart KE, Keradman R, Liu EJ, Wang J, Gillevet PM, Sikaroodi M, Moeller FG, Wade JB. Elderly patients have an altered gut-brain axis regardless of the presence of cirrhosis. Sci Rep. 2016;6:38481. [PMID: 27922089 DOI: 10.1038/srep38481] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
42 Iqbal U, Jadeja RN, Khara HS, Khurana S. A Comprehensive Review Evaluating the Impact of Protein Source (Vegetarian vs. Meat Based) in Hepatic Encephalopathy. Nutrients 2021;13:370. [PMID: 33530344 DOI: 10.3390/nu13020370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Xu J, Zhan Q, Fan Y, Lo EKK, Zhang F, Yu Y, El-Nezami H, Zeng Z. Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management. Pathogens 2021;10:782. [PMID: 34206200 DOI: 10.3390/pathogens10070782] [Reference Citation Analysis]
44 Aday A, O'Leary JG. Acute on Chronic Liver Failure: Definition and Implications. Clin Liver Dis 2020;24:521-34. [PMID: 32620286 DOI: 10.1016/j.cld.2020.04.004] [Reference Citation Analysis]
45 Arab JP, Martin-Mateos RM, Shah VH. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int. 2018;12:24-33. [PMID: 28550391 DOI: 10.1007/s12072-017-9798-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 11.6] [Reference Citation Analysis]
46 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
47 Prifti E, Chevaleyre Y, Hanczar B, Belda E, Danchin A, Clément K, Zucker JD. Interpretable and accurate prediction models for metagenomics data. Gigascience 2020;9:giaa010. [PMID: 32150601 DOI: 10.1093/gigascience/giaa010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
48 Grąt M, Wronka KM, Lewandowski Z, Grąt K, Krasnodębski M, Stypułkowski J, Hołówko W, Masior Ł, Kosińska I, Wasilewicz M, Raszeja-wyszomirska J, Rejowski S, Bik E, Patkowski W, Krawczyk M. Effects of continuous use of probiotics before liver transplantation: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition 2017;36:1530-9. [DOI: 10.1016/j.clnu.2017.04.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
49 Das P, Marcišauskas S, Ji B, Nielsen J. Metagenomic analysis of bile salt biotransformation in the human gut microbiome. BMC Genomics 2019;20:517. [PMID: 31234773 DOI: 10.1186/s12864-019-5899-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
50 Zhou Z, Zhong W. Targeting the gut barrier for the treatment of alcoholic liver disease. Liver Res 2017;1:197-207. [PMID: 30034913 DOI: 10.1016/j.livres.2017.12.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
51 Merli M, Iebba V, Giusto M. What is new about diet in hepatic encephalopathy. Metab Brain Dis. 2016;31:1289-1294. [PMID: 26419384 DOI: 10.1007/s11011-015-9734-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
52 Kang DJ, Hylemon PB, Bajaj JS. Fecal transplant to mitigate hyperammonemia and hepatic encephalopathy in animal models. Annals of Hepatology 2015;14:762-3. [DOI: 10.1016/s1665-2681(19)30774-4] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Cold F, Baunwall SMD, Dahlerup JF, Petersen AM, Hvas CL, Hansen LH. Systematic review with meta-analysis: encapsulated faecal microbiota transplantation - evidence for clinical efficacy. Therap Adv Gastroenterol 2021;14:17562848211041004. [PMID: 34484424 DOI: 10.1177/17562848211041004] [Reference Citation Analysis]
54 Arif M, Zhang C, Li X, Güngör C, Çakmak B, Arslantürk M, Tebani A, Özcan B, Subaş O, Zhou W, Piening B, Turkez H, Fagerberg L, Price N, Hood L, Snyder M, Nielsen J, Uhlen M, Mardinoglu A. iNetModels 2.0: an interactive visualization and database of multi-omics data. Nucleic Acids Res 2021;49:W271-6. [PMID: 33849075 DOI: 10.1093/nar/gkab254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
55 Meyer F, Bannert K, Wiese M, Esau S, Sautter LF, Ehlers L, Aghdassi AA, Metges CC, Garbe LA, Jaster R, Lerch MM, Lamprecht G, Valentini L. Molecular Mechanism Contributing to Malnutrition and Sarcopenia in Patients with Liver Cirrhosis. Int J Mol Sci 2020;21:E5357. [PMID: 32731496 DOI: 10.3390/ijms21155357] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
56 Hu J, Luo J, Zhang M, Wu J, Zhang Y, Kong H, Qu H, Cheng G, Zhao Y. Protective Effects of Radix Sophorae Flavescentis Carbonisata-Based Carbon Dots Against Ethanol-Induced Acute Gastric Ulcer in Rats: Anti-Inflammatory and Antioxidant Activities. Int J Nanomedicine 2021;16:2461-75. [PMID: 33814910 DOI: 10.2147/IJN.S289515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kim SE, Park JW, Kim HS, Jang MK, Suk KT, Kim DJ. The Role of Gut Dysbiosis in Acute-on-Chronic Liver Failure. Int J Mol Sci 2021;22:11680. [PMID: 34769109 DOI: 10.3390/ijms222111680] [Reference Citation Analysis]
58 Bajaj JS, Sikaroodi M, Shamsaddini A, Henseler Z, Santiago-Rodriguez T, Acharya C, Fagan A, Hylemon PB, Fuchs M, Gavis E, Ward T, Knights D, Gillevet PM. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut 2021;70:1162-73. [PMID: 32998876 DOI: 10.1136/gutjnl-2020-322470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
59 Altay O, Nielsen J, Uhlen M, Boren J, Mardinoglu A. Systems biology perspective for studying the gut microbiota in human physiology and liver diseases. EBioMedicine 2019;49:364-73. [PMID: 31636011 DOI: 10.1016/j.ebiom.2019.09.057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
60 Bajaj JS, Matin P, White MB, Fagan A, Deeb JG, Acharya C, Dalmet SS, Sikaroodi M, Gillevet PM, Sahingur SE. Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis. Am J Physiol Gastrointest Liver Physiol 2018;315:G824-37. [PMID: 30118351 DOI: 10.1152/ajpgi.00230.2018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
61 Fairfield B, Schnabl B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep 2021;3:100220. [PMID: 33598648 DOI: 10.1016/j.jhepr.2020.100220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Zhang N, Gou Y, Liang S, Chen N, Liu Y, He Q, Zhang J. Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response. J Immunol Res 2021;2021:4973589. [PMID: 34722779 DOI: 10.1155/2021/4973589] [Reference Citation Analysis]
63 Sarangi AN, Goel A, Singh A, Sasi A, Aggarwal R. Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration. BMC Gastroenterol 2017;17:125. [PMID: 29179682 DOI: 10.1186/s12876-017-0683-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
64 Righi E. Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions. World J Gastroenterol 2018; 24(38): 4311-4329 [PMID: 30344417 DOI: 10.3748/wjg.v24.i38.4311] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
65 Yi Z, Xia Y, Liu X, Wang G, Xiong Z, Ai L. Antrodin A from mycelium of Antrodia camphorata alleviates acute alcoholic liver injury and modulates intestinal flora dysbiosis in mice. Journal of Ethnopharmacology 2020;254:112681. [DOI: 10.1016/j.jep.2020.112681] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
66 Derovs A, Laivacuma S, Krumina A. Targeting Microbiota: What Do We Know about It at Present? Medicina (Kaunas) 2019;55:E459. [PMID: 31405111 DOI: 10.3390/medicina55080459] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
67 Huang ZA, Chen X, Zhu Z, Liu H, Yan GY, You ZH, Wen Z. PBHMDA: Path-Based Human Microbe-Disease Association Prediction. Front Microbiol 2017;8:233. [PMID: 28275370 DOI: 10.3389/fmicb.2017.00233] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
68 Laleman W, Claria J, Van der Merwe S, Moreau R, Trebicka J. Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough. Can J Gastroenterol Hepatol 2018;2018:1027152. [PMID: 30155448 DOI: 10.1155/2018/1027152] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
69 Flamm SL, Mullen KD, Heimanson Z, Sanyal AJ. Rifaximin has the potential to prevent complications of cirrhosis. Therap Adv Gastroenterol. 2018;11:1756284818800307. [PMID: 30283499 DOI: 10.1177/1756284818800307] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
70 Enright EF, Griffin BT, Gahan CG, Joyce SA. Microbiome-mediated bile acid modification: Role in intestinal drug absorption and metabolism. Pharmacological Research 2018;133:170-86. [DOI: 10.1016/j.phrs.2018.04.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
71 Horvath A, Stadlbauer V. [Proton Pump Inhibitors and their Microbiome-Mediated Side Effects]. Zentralbl Chir 2021;146:165-9. [PMID: 33327006 DOI: 10.1055/a-1312-7587] [Reference Citation Analysis]
72 Elwir S, Rahimi RS. Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. J Clin Transl Hepatol. 2017;5:142-151. [PMID: 28660152 DOI: 10.14218/jcth.2016.00069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
73 Xu P, Liu P, Zhou C, Shi Y, Wu Q, Yang Y, Li G, Hu G, Guo X. A Multi-Omics Study of Chicken Infected by Nephropathogenic Infectious Bronchitis Virus. Viruses 2019;11:E1070. [PMID: 31744152 DOI: 10.3390/v11111070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
74 Wellhöner F, Döscher N, Woelfl F, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Pieper DH, Cornberg M, Wedemeyer H, Heidrich B. Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. Hepatology 2021;74:72-82. [PMID: 33411981 DOI: 10.1002/hep.31700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Kwong EK, Puri P. Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease. Transl Gastroenterol Hepatol 2021;6:3. [PMID: 33409398 DOI: 10.21037/tgh.2020.02.18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
76 Sharma SP, Suk KT, Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27(37): 6161-6179 [PMID: 34712025 DOI: 10.3748/wjg.v27.i37.6161] [Reference Citation Analysis]
77 Grąt M, Hołówko W, Wronka KM, Grąt K, Lewandowski Z, Kosińska I, Krasnodębski M, Wasilewicz M, Gałęcka M, Szachta P, Zborowska H, Patkowski W, Krawczyk M. The relevance of intestinal dysbiosis in liver transplant candidates. Transpl Infect Dis 2015;17:174-84. [PMID: 25728703 DOI: 10.1111/tid.12352] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
78 Gu Z, Liu Y, Hu S, You Y, Wen J, Li W, Wang Y. Probiotics for Alleviating Alcoholic Liver Injury. Gastroenterol Res Pract 2019;2019:9097276. [PMID: 31263495 DOI: 10.1155/2019/9097276] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
79 Meissner EG. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression? Clin Infect Dis 2018;67:878-80. [PMID: 29718134 DOI: 10.1093/cid/ciy208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
80 Reuter B, Bajaj JS. Microbiome: Emerging Concepts in Patients with Chronic Liver Disease.Clin Liver Dis. 2020;24:493-520. [PMID: 32620285 DOI: 10.1016/j.cld.2020.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
81 Mikkelsen KH, Allin KH, Knop FK. Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature. Diabetes Obes Metab. 2016;18:444-453. [PMID: 26818734 DOI: 10.1111/dom.12637] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
82 Tu Q, Li J, Shi Z, Chen Y, Lin L, Li J, Wang H, Yan J, Zhou Q, Li X, Li L, Zhou J, He Z. HuMiChip2 for strain level identification and functional profiling of human microbiomes. Appl Microbiol Biotechnol 2017;101:423-35. [PMID: 27734124 DOI: 10.1007/s00253-016-7910-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
83 Giuffrè M, Campigotto M, Campisciano G, Comar M, Crocè LS. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. Am J Physiol Gastrointest Liver Physiol 2020;318:G889-906. [PMID: 32146836 DOI: 10.1152/ajpgi.00161.2019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
84 Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H, Xie H, Chen X, Shao L, Zhang R, Xu S, Zhang H, Cui G, Sun R, Wen H, Lerut JP, Kan Q, Li L, Zheng S. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68:1014-1023. [PMID: 30045880 DOI: 10.1136/gutjnl-2017-315084] [Cited by in Crossref: 156] [Cited by in F6Publishing: 154] [Article Influence: 39.0] [Reference Citation Analysis]
85 Bruneau A, Hundertmark J, Guillot A, Tacke F. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Front Med (Lausanne) 2021;8:725390. [PMID: 34650994 DOI: 10.3389/fmed.2021.725390] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Betrapally NS, Gillevet PM, Bajaj JS. Gut microbiome and liver disease. Transl Res. 2017;179:49-59. [PMID: 27477080 DOI: 10.1016/j.trsl.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
87 Piano S, Brocca A, Mareso S, Angeli P. Infections complicating cirrhosis. Liver Int. 2018;38 Suppl 1:126-133. [PMID: 29427501 DOI: 10.1111/liv.13645] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 18.7] [Reference Citation Analysis]
88 Anand G, Zarrinpar A, Loomba R. Targeting Dysbiosis for the Treatment of Liver Disease. Semin Liver Dis. 2016;36:37-47. [PMID: 26870931 DOI: 10.1055/s-0035-1571276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
89 Bajaj JS. Liver capsule: Hepatic encephalopathy. Hepatology 2015;62:955. [PMID: 26178915 DOI: 10.1002/hep.27984] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
90 Delgado-Venegas CS, Martínez-Hernández SL, Cervantes-García D, Montes de Oca-Luna R, de Jesús Loera-Arias M, Mata-Martínez MG, Ventura-Juárez J, Muñoz-Ortega MH. Modulating effects of the probiotic Lactococcus lactis on the hepatic fibrotic process induced by CCl4 in Wistar rats. Exp Ther Med 2021;21:339. [PMID: 33732312 DOI: 10.3892/etm.2021.9770] [Reference Citation Analysis]
91 Yan K, Hung A, Parmer C, Yang H, Jain D, Lim B, Goodman AL, Garcia-Tsao G. Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites. Hepatol Commun 2021;5:1507-17. [PMID: 34510838 DOI: 10.1002/hep4.1740] [Reference Citation Analysis]
92 Yamamoto K, Honda T, Ito T, Ishizu Y, Kuzuya T, Nakamura M, Miyahara R, Kawashima H, Ishigami M, Fujishiro M. The relationship between oral-origin bacteria in the fecal microbiome and albumin-bilirubin grade in patients with hepatitis C. J Gastroenterol Hepatol 2021;36:790-9. [PMID: 32744764 DOI: 10.1111/jgh.15206] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Schwenger KJ, Clermont-Dejean N, Allard JP. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Rep 2019;1:214-26. [PMID: 32039372 DOI: 10.1016/j.jhepr.2019.04.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
94 Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut. Dig Dis 2015;33:338-45. [PMID: 26045267 DOI: 10.1159/000371678] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
95 Yamamoto K, Ishigami M, Honda T, Takeyama T, Ito T, Ishizu Y, Kuzuya T, Hayashi K, Goto H, Hirooka Y. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hepatol Int 2019;13:234-44. [DOI: 10.1007/s12072-019-09932-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
96 Macnaughtan J, Jalan R. Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis. American Journal of Gastroenterology 2015;110:1399-410. [DOI: 10.1038/ajg.2015.313] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
97 Lv LX, Fang DQ, Shi D, Chen DY, Yan R, Zhu YX, Chen YF, Shao L, Guo FF, Wu WR, Li A, Shi HY, Jiang XW, Jiang HY, Xiao YH, Zheng SS, Li LJ. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ Microbiol. 2016;18:2272-2286. [PMID: 27243236 DOI: 10.1111/1462-2920.13401] [Cited by in Crossref: 96] [Cited by in F6Publishing: 96] [Article Influence: 19.2] [Reference Citation Analysis]
98 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
99 Kriss M, Hazleton KZ, Nusbacher NM, Martin CG, Lozupone CA. Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol. 2018;44:34-40. [PMID: 30036705 DOI: 10.1016/j.mib.2018.07.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 26.3] [Reference Citation Analysis]
100 Piñero F, Vazquez M, Baré P, Rohr C, Mendizabal M, Sciara M, Alonso C, Fay F, Silva M. A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma. Ann Hepatol 2019;18:480-7. [PMID: 31023615 DOI: 10.1016/j.aohep.2018.10.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
101 Trexel J, Yoon GS, Keswani RK, McHugh C, Yeomans L, Vitvitsky V, Banerjee R, Sud S, Sun Y, Rosania GR, Stringer KA. Macrophage-Mediated Clofazimine Sequestration Is Accompanied by a Shift in Host Energy Metabolism. J Pharm Sci 2017;106:1162-74. [PMID: 28007559 DOI: 10.1016/j.xphs.2016.12.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
102 Font-Burgada J, Sun B, Karin M. Obesity and Cancer: The Oil that Feeds the Flame. Cell Metab. 2016;23:48-62. [PMID: 26771116 DOI: 10.1016/j.cmet.2015.12.015] [Cited by in Crossref: 197] [Cited by in F6Publishing: 171] [Article Influence: 32.8] [Reference Citation Analysis]
103 Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. Int J Mol Sci. 2020;21:5254. [PMID: 32722100 DOI: 10.3390/ijms21155254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
104 Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Gut-liver axis in cirrhosis: Are hemodynamic changes a missing link? World J Clin Cases 2021; 9(31): 9320-9332 [PMID: 34877269 DOI: 10.12998/wjcc.v9.i31.9320] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Kumar JA, Teckman JH. Controversies in the Mechanism of Total Parenteral Nutrition Induced Pathology. Children (Basel) 2015;2:358-70. [PMID: 27417369 DOI: 10.3390/children2030358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
106 Ling Z, Liu X, Cheng Y, Jiang X, Jiang H, Wang Y, Li L. Decreased Diversity of the Oral Microbiota of Patients with Hepatitis B Virus-Induced Chronic Liver Disease: A Pilot Project. Sci Rep. 2015;5:17098. [PMID: 26606973 DOI: 10.1038/srep17098] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 6.6] [Reference Citation Analysis]
107 Gómez-Hurtado I, Such J, Francés R. Microbiome and bacterial translocation in cirrhosis. Gastroenterol Hepatol 2016;39:687-96. [PMID: 26775042 DOI: 10.1016/j.gastrohep.2015.10.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
108 Middleton P, Hsu C, Lythgoe MP. Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies. BMJ Open Gastroenterol 2021;8:e000739. [PMID: 34675033 DOI: 10.1136/bmjgast-2021-000739] [Reference Citation Analysis]
109 Fasullo M, Rau P, Liu DQ, Holzwanger E, Mathew JP, Guilarte-Walker Y, Szabo G. Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients. World J Hepatol 2019; 11(6): 522-530 [PMID: 31293720 DOI: 10.4254/wjh.v11.i6.522] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
110 Watt KD. The evolving role of the microbiome in liver failure and liver transplantation. Liver Transpl 2016;22:58-61. [PMID: 27588961 DOI: 10.1002/lt.24623] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
111 Bajaj JS, Shamsaddini A, Acharya C, Fagan A, Sikaroodi M, Gavis E, McGeorge S, Khoruts A, Fuchs M, Sterling RK, Lee H, Gillevet PM. Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis. Gut Microbes 2021;13:1993584. [PMID: 34743650 DOI: 10.1080/19490976.2021.1993584] [Reference Citation Analysis]
112 Neong SF, Adebayo D, Wong F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Rev Gastroenterol Hepatol 2019;13:293-305. [PMID: 30791777 DOI: 10.1080/17474124.2018.1555469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
113 Edwards LA, Goldenberg SD, Shawcross DL. Meeting the Challenge of Antimicrobial Resistance in Cirrhosis: The Invisible Threat That Lies Within. Gastroenterology 2021;161:413-5. [PMID: 34048780 DOI: 10.1053/j.gastro.2021.05.043] [Reference Citation Analysis]
114 Chi X, Pan CQ, Liu S, Cheng D, Cao Z, Xing H. Regulating Intestinal Microbiota in the Prevention and Treatment of Alcohol-Related Liver Disease. Can J Gastroenterol Hepatol 2020;2020:6629196. [PMID: 33381475 DOI: 10.1155/2020/6629196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
115 Zheng Y, Yue C, Zhang H, Chen H, Liu Y, Li J. Deoxycholic Acid and Lithocholic Acid Alleviate Liver Injury and Inflammation in Mice with Klebsiella pneumoniae-Induced Liver Abscess and Bacteremia. J Inflamm Res 2021;14:777-89. [PMID: 33727851 DOI: 10.2147/JIR.S298495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. 2017;153:35-48. [PMID: 28528705 DOI: 10.1053/j.gastro.2017.04.047] [Cited by in Crossref: 198] [Cited by in F6Publishing: 146] [Article Influence: 39.6] [Reference Citation Analysis]
117 Ryu KH. [Gut Microbiota and Pancreatobiliary System]. Korean J Gastroenterol 2020;75:231-9. [PMID: 32448854 DOI: 10.4166/kjg.2020.75.5.231] [Reference Citation Analysis]
118 Maslennikov R, Ivashkin V, Efremova I, Alieva A, Kashuh E, Tsvetaeva E, Poluektova E, Shirokova E, Ivashkin K. Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis. World J Hepatol 2021; 13(5): 557-570 [PMID: 34131470 DOI: 10.4254/wjh.v13.i5.557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
119 Wiest R. The Gut Microbiome and Cirrhosis: Basic Aspects. In: de Franchis R, editor. Portal Hypertension VI. Cham: Springer International Publishing; 2016. pp. 139-68. [DOI: 10.1007/978-3-319-23018-4_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
120 Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65:2035-2044. [PMID: 27802157 DOI: 10.1136/gutjnl-2016-312729] [Cited by in Crossref: 202] [Cited by in F6Publishing: 186] [Article Influence: 33.7] [Reference Citation Analysis]
121 Pérez-Matute P, Íñiguez M, Villanueva-Millán MJ, Recio-Fernández E, Vázquez AM, Sánchez SC, Morano LE, Oteo JA. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients.Eur J Intern Med. 2019;67:47-58. [PMID: 31221551 DOI: 10.1016/j.ejim.2019.06.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
122 Shah RM, McKenzie EJ, Rosin MT, Jadhav SR, Gondalia SV, Rosendale D, Beale DJ. An Integrated Multi-Disciplinary Perspectivefor Addressing Challenges of the Human Gut Microbiome. Metabolites 2020;10:E94. [PMID: 32155792 DOI: 10.3390/metabo10030094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
123 Huan H, Hu H, Chen XH, Gao WN, Li LL, Li J, Deng K, Liu C. Diversity of intestinal microflora in tibetan patients with liver cirrhosis based on high-throughput sequencing. Shijie Huaren Xiaohua Zazhi 2019; 27(18): 1142-1148 [DOI: 10.11569/wcjd.v27.i18.1142] [Reference Citation Analysis]
124 Lau LHS, Wong SH. Microbiota, Obesity and NAFLD. Adv Exp Med Biol. 2018;1061:111-125. [PMID: 29956210 DOI: 10.1007/978-981-10-8684-7_9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
125 Tilg H, Grander C, Moschen AR. How does the microbiome affect liver disease? Clin Liver Dis (Hoboken) 2016;8:123-6. [PMID: 31041079 DOI: 10.1002/cld.586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
126 Pan X, Kaminga AC, Liu A, Wen SW, Luo M, Luo J. Gut Microbiota, Glucose, Lipid, and Water-Electrolyte Metabolism in Children With Nonalcoholic Fatty Liver Disease. Front Cell Infect Microbiol 2021;11:683743. [PMID: 34778099 DOI: 10.3389/fcimb.2021.683743] [Reference Citation Analysis]
127 Hellerbrand C, Schattenberg JM, Peterburs P, Lechner A, Brignoli R. The potential of silymarin for the treatment of hepatic disorders. Clin Phytosci 2017;2. [DOI: 10.1186/s40816-016-0019-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
128 Li F, Duan K, Wang C, McClain C, Feng W. Probiotics and Alcoholic Liver Disease: Treatment and Potential Mechanisms. Gastroenterol Res Pract. 2016;2016:5491465. [PMID: 26839540 DOI: 10.1155/2016/5491465.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 Kang SH, Lee YB, Lee JH, Nam JY, Chang Y, Cho H, Yoo JJ, Cho YY, Cho EJ, Yu SJ, Kim MY, Kim YJ, Baik SK, Yoon JH. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Aliment Pharmacol Ther. 2017;46:845-855. [PMID: 28836723 DOI: 10.1111/apt.14275] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
130 Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang J, Gurry T, Williams R, Sikaroodi M, Fuchs M, Alm E, John B, Thacker LR, Riva A, Smith M, Taylor-Robinson SD, Gillevet PM. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017;66:1727-1738. [PMID: 28586116 DOI: 10.1002/hep.29306] [Cited by in Crossref: 254] [Cited by in F6Publishing: 212] [Article Influence: 50.8] [Reference Citation Analysis]
131 Barbuti RC, Schiavon LL, Oliveira CP, Alvares-DA-Silva MR, Sassaki LY, Passos MDCF, Farias AQ, Barros LL, Barreto BP, Albuquerque GBML, Alves AM, Navarro-Rodriguez T, Bittencourt PL. GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBG). Arq Gastroenterol 2020;57:381-98. [PMID: 33331485 DOI: 10.1590/S0004-2803.202000000-72] [Reference Citation Analysis]
132 Duong N, Bajaj JS. The impact of the gut microbiome on liver transplantation. Curr Opin Organ Transplant 2021;26:587-94. [PMID: 34636770 DOI: 10.1097/MOT.0000000000000930] [Reference Citation Analysis]
133 Pringle PL, Soto MT, Chung RT, Hohmann E. Patients With Cirrhosis Require More Fecal Microbiota Capsules to Cure Refractory and Recurrent Clostridium difficile Infections. Clin Gastroenterol Hepatol. 2019;17:791-793. [PMID: 29859984 DOI: 10.1016/j.cgh.2018.05.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
134 Solé C, Guilly S, Da Silva K, Llopis M, Le-Chatelier E, Huelin P, Carol M, Moreira R, Fabrellas N, De Prada G, Napoleone L, Graupera I, Pose E, Juanola A, Borruel N, Berland M, Toapanta D, Casellas F, Guarner F, Doré J, Solà E, Ehrlich SD, Ginès P. Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis. Gastroenterology 2021;160:206-218.e13. [PMID: 32941879 DOI: 10.1053/j.gastro.2020.08.054] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
135 Ferrere G, Wrzosek L, Cailleux F, Turpin W, Puchois V, Spatz M, Ciocan D, Rainteau D, Humbert L, Hugot C, Gaudin F, Noordine M, Robert V, Berrebi D, Thomas M, Naveau S, Perlemuter G, Cassard A. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. Journal of Hepatology 2017;66:806-15. [DOI: 10.1016/j.jhep.2016.11.008] [Cited by in Crossref: 127] [Cited by in F6Publishing: 119] [Article Influence: 25.4] [Reference Citation Analysis]
136 Dubinkina VB, Tyakht AV, Odintsova VY, Yarygin KS, Kovarsky BA, Pavlenko AV, Ischenko DS, Popenko AS, Alexeev DG, Taraskina AY, Nasyrova RF, Krupitsky EM, Shalikiani NV, Bakulin IG, Shcherbakov PL, Skorodumova LO, Larin AK, Kostryukova ES, Abdulkhakov RA, Abdulkhakov SR, Malanin SY, Ismagilova RK, Grigoryeva TV, Ilina EN, Govorun VM. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome. 2017;5:141. [PMID: 29041989 DOI: 10.1186/s40168-017-0359-2] [Cited by in Crossref: 124] [Cited by in F6Publishing: 109] [Article Influence: 24.8] [Reference Citation Analysis]
137 Castillo-Castro C, Martagón-Rosado AJ, Ortiz-Lopez R, Garrido-Treviño LF, Villegas-Albo M, Bosques-Padilla FJ. Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. World J Hepatol 2021; 13(11): 1494-1511 [PMID: 34904026 DOI: 10.4254/wjh.v13.i11.1494] [Reference Citation Analysis]
138 Heidrich B, Vital M, Plumeier I, Döscher N, Kahl S, Kirschner J, Ziegert S, Solbach P, Lenzen H, Potthoff A, Manns MP, Wedemeyer H, Pieper DH. Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls.Liver Int. 2018;38:50-58. [PMID: 28561276 DOI: 10.1111/liv.13485] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
139 Nishimura N, Kaji K, Kitagawa K, Sawada Y, Furukawa M, Ozutsumi T, Fujinaga Y, Tsuji Y, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Fukui H, Yoshiji H. Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. Int J Mol Sci 2021;22:6921. [PMID: 34203178 DOI: 10.3390/ijms22136921] [Reference Citation Analysis]
140 Shen TD, Pyrsopoulos N, Rustgi VK. Microbiota and the liver: Microbiota and the Liver. Liver Transpl 2018;24:539-50. [DOI: 10.1002/lt.25008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
141 Inamine T, Schnabl B. Immunoglobulin A and liver diseases. J Gastroenterol 2018;53:691-700. [PMID: 29075899 DOI: 10.1007/s00535-017-1400-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
142 Litwinowicz K, Choroszy M, Waszczuk E. Changes in the composition of the human intestinal microbiome in alcohol use disorder: a systematic review. The American Journal of Drug and Alcohol Abuse 2020;46:4-12. [DOI: 10.1080/00952990.2019.1669629] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
143 Rattan P, Minacapelli CD, Rustgi V. The Microbiome and Hepatocellular Carcinoma. Liver Transpl. 2020;26:1316-1327. [PMID: 32564483 DOI: 10.1002/lt.25828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
144 Woodhouse CA, Patel VC, Goldenberg S, Sanchez-Fueyo A, China L, O'Brien A, Flach C, Douiri A, Shawcross D. PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial. BMJ Open 2019;9:e023518. [PMID: 30772848 DOI: 10.1136/bmjopen-2018-023518] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
145 Bergheim I, Schuppan D. Microbiome and Diseases: Hepatic Disorders. In: Haller D, editor. The Gut Microbiome in Health and Disease. Cham: Springer International Publishing; 2018. pp. 279-93. [DOI: 10.1007/978-3-319-90545-7_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
146 Bloom PP, Luévano JM Jr, Miller KJ, Chung RT. Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy. Ann Hepatol 2021;25:100333. [PMID: 33621653 DOI: 10.1016/j.aohep.2021.100333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Peleman C, Camilleri M. Rifaximin, Microbiota Biology, and Hepatic Encephalopathy. Clin Transl Gastroenterol 2016;7:e195. [PMID: 27711069 DOI: 10.1038/ctg.2016.52] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
148 Van Nieuwenhove T, Rasschaert G, Kharagjitsingh A, Keymeulen B, Reynaert H, Kindt S. The prevalence of disorders of the gut-brain axis in type 2 diabetes mellitus patients with metabolic dysfunction-associated fatty liver disease: an observational study. Acta Gastroenterol Belg 2021;84:541-7. [PMID: 34965034 DOI: 10.51821/84.4.003] [Reference Citation Analysis]
149 Saboo K, Petrakov NV, Shamsaddini A, Fagan A, Gavis EA, Sikaroodi M, McGeorge S, Gillevet PM, Iyer RK, Bajaj JS. Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning. J Hepatol 2021:S0168-8278(21)02183-8. [PMID: 34793867 DOI: 10.1016/j.jhep.2021.11.011] [Reference Citation Analysis]
150 Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018;47:192-202. [PMID: 29083037 DOI: 10.1111/apt.14397] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 15.6] [Reference Citation Analysis]
151 Romero-gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. Journal of Hepatology 2015;62:437-47. [DOI: 10.1016/j.jhep.2014.09.005] [Cited by in Crossref: 125] [Cited by in F6Publishing: 100] [Article Influence: 17.9] [Reference Citation Analysis]
152 Campion D, Giovo I, Ponzo P, Saracco GM, Balzola F, Alessandria C. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World J Hepatol 2019; 11(6): 489-512 [PMID: 31293718 DOI: 10.4254/wjh.v11.i6.489] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
153 Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res 2019;209:22-38. [PMID: 30853445 DOI: 10.1016/j.trsl.2019.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
154 Doré J, Multon M, Béhier J, Affagard H, Andremont A, Barthélémy P, Batitsa R, Bonneville M, Bonny C, Boyaval G, Chamaillard M, Chevalier M, Cordaillat-simmons M, Cournarie F, Diaz I, Guillaume E, Guyard C, Jouvin-marche E, Martin F, Petiteau D. The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect? Therapies 2017;72:21-38. [DOI: 10.1016/j.therap.2016.12.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
155 Yuan Y, Wang X, Xu X, Liu Y, Li C, Yang M, Yang Y, Ma Z. Evaluation of a Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and Potential Application in the Treatment of Gastrointestinal and Liver Disorders. ACS Infect Dis 2020;6:820-31. [DOI: 10.1021/acsinfecdis.9b00374] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
156 Bajaj JS, Thacker LR, Fagan A, White MB, Gavis EA, Hylemon PB, Brown R, Acharya C, Heuman DM, Fuchs M, Dalmet S, Sikaroodi M, Gillevet PM. Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis. JCI Insight 2018;3:98019. [PMID: 29515036 DOI: 10.1172/jci.insight.98019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
157 Cai YJ, Dong JJ, Dong JZ, Chen Y, Lin Z, Song M, Wang YQ, Chen YP, Shi KQ, Zhou MT. A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. Aliment Pharmacol Ther. 2017;45:1413-1426. [PMID: 28345155 DOI: 10.1111/apt.14046] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
158 Nishida S, Hamada K, Nishino N, Fukushima D, Koyanagi R, Horikawa Y, Shiwa Y, Saitoh S. Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese. World J Hepatol 2019; 11(6): 531-541 [PMID: 31293721 DOI: 10.4254/wjh.v11.i6.531] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
159 Nadim MK, Durand F, Kellum JA, Levitsky J, O’leary JG, Karvellas CJ, Bajaj JS, Davenport A, Jalan R, Angeli P, Caldwell SH, Fernández J, Francoz C, Garcia-tsao G, Ginès P, Ison MG, Kramer DJ, Mehta RL, Moreau R, Mulligan D, Olson JC, Pomfret EA, Senzolo M, Steadman RH, Subramanian RM, Vincent J, Genyk YS. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. Journal of Hepatology 2016;64:717-35. [DOI: 10.1016/j.jhep.2015.10.019] [Cited by in Crossref: 150] [Cited by in F6Publishing: 111] [Article Influence: 25.0] [Reference Citation Analysis]
160 Márquez M, Fernández Gutiérrez del Álamo C, Girón-González JA. Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunity. World J Gastroenterol 2016; 22(4): 1433-1448 [PMID: 26819512 DOI: 10.3748/wjg.v22.i4.1433] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
161 Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 51.5] [Reference Citation Analysis]
162 Wang Y, Pan CQ, Xing H. Advances in Gut Microbiota of Viral Hepatitis Cirrhosis. Biomed Res Int 2019;2019:9726786. [PMID: 31886272 DOI: 10.1155/2019/9726786] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
163 Shevlyakov A, Nikogosov D, Stewart LA, Toribio-Mateas M. Reference values for intake of six types of soluble and insoluble fibre in healthy UK inhabitants based on the UK Biobank data. Public Health Nutr 2021;:1-15. [PMID: 34105446 DOI: 10.1017/S1368980021002524] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Bi C, Xiao G, Liu C, Yan J, Chen J, Si W, Zhang J, Liu Z. Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer. Front Cell Dev Biol 2021;9:702414. [PMID: 34957088 DOI: 10.3389/fcell.2021.702414] [Reference Citation Analysis]
165 Liang D, Leung RK, Guan W, Au WW. Involvement of gut microbiome in human health and disease: brief overview, knowledge gaps and research opportunities. Gut Pathog. 2018;10:3. [PMID: 29416567 DOI: 10.1186/s13099-018-0230-4] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 19.8] [Reference Citation Analysis]
166 Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F, Fernández J, To U, García-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers 2016;2:16041. [PMID: 27277335 DOI: 10.1038/nrdp.2016.41] [Cited by in Crossref: 159] [Cited by in F6Publishing: 144] [Article Influence: 26.5] [Reference Citation Analysis]
167 Lee NY, Suk KT. The Role of the Gut Microbiome in Liver Cirrhosis Treatment. Int J Mol Sci 2020;22:E199. [PMID: 33379148 DOI: 10.3390/ijms22010199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
168 Ni J, Huang R, Zhou H, Xu X, Li Y, Cao P, Zhong K, Ge M, Chen X, Hou B, Yu M, Peng B, Li Q, Zhang P, Gao Y. Analysis of the Relationship Between the Degree of Dysbiosis in Gut Microbiota and Prognosis at Different Stages of Primary Hepatocellular Carcinoma. Front Microbiol 2019;10:1458. [PMID: 31293562 DOI: 10.3389/fmicb.2019.01458] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
169 Bajaj JS, Fagan A, White MB, Wade JB, Hylemon PB, Heuman DM, Fuchs M, John BV, Acharya C, Sikaroodi M, Gillevet PM. Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy. Am J Gastroenterol. 2019;. [PMID: 30816877 DOI: 10.14309/ajg.0000000000000102] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
170 Chen J, Ryu E, Hathcock M, Ballman K, Chia N, Olson JE, Nelson H. Impact of demographics on human gut microbial diversity in a US Midwest population. PeerJ. 2016;4:e1514. [PMID: 26839739 DOI: 10.7717/peerj.1514] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
171 Mohandas S, Vairappan B. Ginkgolide-A attenuates bacterial translocation through activating PXR and improving antimicrobial peptide Reg 3A in experimental cirrhosis. Life Sciences 2020;257:118111. [DOI: 10.1016/j.lfs.2020.118111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
172 Bajaj JS, Betrapally NS, Gillevet PM. Decompensated cirrhosis and microbiome interpretation. Nature 2015;525:E1-2. [PMID: 26381988 DOI: 10.1038/nature14851] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
173 Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. World J Gastroenterol 2019; 25(39): 5897-5917 [PMID: 31660028 DOI: 10.3748/wjg.v25.i39.5897] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
174 Bajaj JS, Liu EJ, Kheradman R, Fagan A, Heuman DM, White M, Gavis EA, Hylemon P, Sikaroodi M, Gillevet PM. Fungal dysbiosis in cirrhosis. Gut 2018;67:1146-54. [DOI: 10.1136/gutjnl-2016-313170] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 10.4] [Reference Citation Analysis]
175 Yang Y, Ai G, Wang M. Alcoholic liver disease and intestinal microecology. Shijie Huaren Xiaohua Zazhi 2019; 27(1): 43-49 [DOI: 10.11569/wcjd.v27.i1.43] [Reference Citation Analysis]
176 Hsu CF, Huang CC, Liu TT, Yang UC, Liu CW, Huang SF, Yang YY, Huang YH, Hou MC, Lin HC. Deletion of intestinal SIRT1 exacerbated muscle wasting in cirrhotic mice by decreasing the intestinal concentration of short-chain fatty acids and inflammation. J Pharmacol Sci 2021;147:376-85. [PMID: 34663520 DOI: 10.1016/j.jphs.2021.09.003] [Reference Citation Analysis]
177 Sehgal R, Bedi O, Trehanpati N. Role of Microbiota in Pathogenesis and Management of Viral Hepatitis.Front Cell Infect Microbiol. 2020;10:341. [PMID: 32850467 DOI: 10.3389/fcimb.2020.00341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
178 Howell J, Pinato DJ, Ramaswami R, Arizumi T, Ferrari C, Gibbin A, Burlone ME, Guaschino G, Toniutto P, Black J. Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. Oncotarget. 2017;8:36161-36170. [PMID: 28212535 DOI: 10.18632/oncotarget.15322] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
179 Basson A, Trotter A, Rodriguez-Palacios A, Cominelli F. Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel Disease. Front Immunol. 2016;7:290. [PMID: 27531998 DOI: 10.3389/fimmu.2016.00290] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
180 Capurso G, Lahner E. The interaction between smoking, alcohol and the gut microbiome. Best Pract Res Clin Gastroenterol. 2017;31:579-588. [PMID: 29195678 DOI: 10.1016/j.bpg.2017.10.006] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 15.6] [Reference Citation Analysis]
181 Hong SJ, Feuerstadt P, Brandt LJ. MELD is the only predictor of short-term mortality in cirrhotic patients with C. difficile infection. Digestive and Liver Disease 2019;51:275-80. [DOI: 10.1016/j.dld.2018.07.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
182 Gao B, Duan Y, Lang S, Barupal D, Wu TC, Valdiviez L, Roberts B, Choy YY, Shen T, Byram G, Zhang Y, Fan S, Wancewicz B, Shao Y, Vervier K, Wang Y, Zhou R, Jiang L, Nath S, Loomba R, Abraldes JG, Bataller R, Tu XM, Stärkel P, Lawley TD, Fiehn O, Schnabl B. Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Co-Metabolism in Patients With Alcoholic Hepatitis. Hepatol Commun 2020;4:1168-82. [PMID: 32766476 DOI: 10.1002/hep4.1537] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
183 Patel V, Lee S, McPhail M, Da Silva K, Guilly S, Zamalloa A, Witherden E, Støy S, Manakkat Vijay GK, Pons N, Galleron N, Huang X, Gencer S, Coen M, Tranah TH, Wendon JA, Bruce K, Le Chatelier E, Ehrlich SD, Edwards LA, Shoaie S, Shawcross DL. Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J Hepatol 2021:S0168-8278(21)02040-7. [PMID: 34571050 DOI: 10.1016/j.jhep.2021.09.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Fomenky BE, Do DN, Talbot G, Chiquette J, Bissonnette N, Chouinard YP, Lessard M, Ibeagha-Awemu EM. Direct-fed microbial supplementation influences the bacteria community composition of the gastrointestinal tract of pre- and post-weaned calves. Sci Rep 2018;8:14147. [PMID: 30237565 DOI: 10.1038/s41598-018-32375-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
185 Fukui H. Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update. Gut Liver 2021;15:666-76. [PMID: 33071239 DOI: 10.5009/gnl20032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
186 Li D, Xi W, Zhang Z, Ren L, Deng C, Chen J, Sun C, Zhang N, Xu J. Oral microbial community analysis of the patients in the progression of liver cancer. Microb Pathog 2020;149:104479. [PMID: 32920149 DOI: 10.1016/j.micpath.2020.104479] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
187 Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int. 2019;39:598-609. [PMID: 30312513 DOI: 10.1111/liv.13986] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
188 Gupta T, Lochan D, Verma N, Rathi S, Agrawal S, Duseja A, Taneja S, Chawla YK, Dhiman RK. Prediction of 28-day mortality in acute decompensation of cirrhosis through the presence of multidrug-resistant infections at admission. J Gastroenterol Hepatol 2020;35:461-6. [PMID: 31334860 DOI: 10.1111/jgh.14788] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
189 Dai W, Sheng Z, Chen J, Xiong J. Shrimp disease progression increases the gut bacterial network complexity and abundances of keystone taxa. Aquaculture 2020;517:734802. [DOI: 10.1016/j.aquaculture.2019.734802] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
190 Ponziani FR, Picca A, Marzetti E, Calvani R, Conta G, Del Chierico F, Capuani G, Faccia M, Fianchi F, Funaro B, Josè Coelho-Junior H, Petito V, Rinninella E, Paroni Sterbini F, Reddel S, Vernocchi P, Cristina Mele M, Miccheli A, Putignani L, Sanguinetti M, Pompili M, Gasbarrini A; GuLiver study group. Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia. Liver Int 2021;41:1320-34. [PMID: 33713524 DOI: 10.1111/liv.14876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
191 Mücke MM, Rüschenbaum S, Mayer A, Mücke VT, Schwarzkopf KM, Zeuzem S, Kehrmann J, Scholtysik R, Lange CM. Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis: an exploratory study. Gut Pathog 2020;12:51. [PMID: 33133240 DOI: 10.1186/s13099-020-00389-y] [Reference Citation Analysis]
192 Pérez-monter C, Escalona-nandez I, Estanes-hernández A, Noriega-lópez L, Torre-delgadillo A. Determinación de la microbiota intestinal en pacientes cirróticos de población mestizo-mexicana. Revista de Gastroenterología de México 2019;84:26-35. [DOI: 10.1016/j.rgmx.2018.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
193 Arroyo V, Angeli P, Moreau R, Jalan R, Clària J, Trebicka J, Fernández J, Gustot T, Caraceni P, Bernardi M; investigators from the EASL-CLIF Consortium, Grifols Chair and European Foundation for the Study of Chronic Liver Failure (EF-Clif). The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol 2021;74:670-85. [PMID: 33301825 DOI: 10.1016/j.jhep.2020.11.048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
194 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
195 Xu P, Shi Y, Liu P, Yang Y, Zhou C, Li G, Luo J, Zhang C, Cao H, Hu G, Guo X. 16S rRNA gene sequencing reveals an altered composition of the gut microbiota in chickens infected with a nephropathogenic infectious bronchitis virus. Sci Rep 2020;10:3556. [PMID: 32103130 DOI: 10.1038/s41598-020-60564-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Raj AS, Shanahan ER, Tran CD, Bhat P, Fletcher LM, Vesey DA, Morrison M, Holtmann G, Macdonald GA. Dysbiosis of the Duodenal Mucosal Microbiota Is Associated With Increased Small Intestinal Permeability in Chronic Liver Disease. Clin Transl Gastroenterol 2019;10:e00068. [PMID: 31373933 DOI: 10.14309/ctg.0000000000000068] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
197 Bajaj JS, Kakiyama G, Zhao D, Takei H, Fagan A, Hylemon P, Zhou H, Pandak WM, Nittono H, Fiehn O, Salzman N, Holtz M, Simpson P, Gavis EA, Heuman DM, Liu R, Kang DJ, Sikaroodi M, Gillevet PM. Continued Alcohol Misuse in Human Cirrhosis is Associated with an Impaired Gut-Liver Axis. Alcohol Clin Exp Res 2017;41:1857-65. [DOI: 10.1111/acer.13498] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
198 Siddiqui MT, Cresci GAM. Microbiota reprogramming for treatment of alcohol-related liver disease. Transl Res 2020;226:26-38. [PMID: 32687975 DOI: 10.1016/j.trsl.2020.07.004] [Reference Citation Analysis]
199 Sung CM, Lin YF, Chen KF, Ke HM, Huang HY, Gong YN, Tsai WS, You JF, Lu MJ, Cheng HT, Lin CY, Kuo CJ, Tsai IJ, Hsieh SY. Predicting Clinical Outcomes of Cirrhosis Patients With Hepatic Encephalopathy From the Fecal Microbiome. Cell Mol Gastroenterol Hepatol. 2019;8:301-318.e2. [PMID: 31004827 DOI: 10.1016/j.jcmgh.2019.04.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
200 Mills S, Stanton C, Lane JA, Smith GJ, Ross RP. Precision Nutrition and the Microbiome, Part I: Current State of the Science. Nutrients. 2019;11:923. [PMID: 31022973 DOI: 10.3390/nu11040923] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 25.7] [Reference Citation Analysis]
201 Ancona G, Alagna L, Lombardi A, Palomba E, Castelli V, Renisi G, Dondossola D, Iavarone M, Muscatello A, Gori A, Bandera A. The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections. Infect Immun 2021;89:e0037621. [PMID: 34460287 DOI: 10.1128/IAI.00376-21] [Reference Citation Analysis]
202 Stadlbauer V, Komarova I, Klymiuk I, Durdevic M, Reisinger A, Blesl A, Rainer F, Horvath A. Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis. Liver Int 2020;40:866-77. [PMID: 31943691 DOI: 10.1111/liv.14382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
203 Lelouvier B, Servant F, Païssé S, Brunet AC, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, Federici M, Fernández-Real JM, Burcelin R, Amar J. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. Hepatology 2016;64:2015-27. [PMID: 27639192 DOI: 10.1002/hep.28829] [Cited by in Crossref: 125] [Cited by in F6Publishing: 115] [Article Influence: 25.0] [Reference Citation Analysis]
204 van de Guchte M, Blottière HM, Doré J. Humans as holobionts: implications for prevention and therapy. Microbiome 2018;6:81. [PMID: 29716650 DOI: 10.1186/s40168-018-0466-8] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 15.0] [Reference Citation Analysis]
205 Woodhouse C, Singanayagam A, Patel VC. Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis. Clin Med (Lond) 2020;20:493-500. [PMID: 32934044 DOI: 10.7861/clinmed.2020-0676] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Tsai CF, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, Hou MC, Lee FY, Su TP, Lu CL. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology. 2017;152:134-141. [PMID: 27639806 DOI: 10.1053/j.gastro.2016.09.007] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 14.3] [Reference Citation Analysis]
207 Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 2016;65:1232-1244. [PMID: 27515775 DOI: 10.1016/j.jhep.2016.07.040] [Cited by in Crossref: 235] [Cited by in F6Publishing: 203] [Article Influence: 39.2] [Reference Citation Analysis]
208 Kang DJ, Hylemon PB, Gillevet PM, Sartor RB, Betrapally NS, Kakiyama G, Sikaroodi M, Takei H, Nittono H, Zhou H, Pandak WM, Yang J, Jiao C, Li X, Lippman HR, Heuman DM, Bajaj JS. Gut microbial composition can differentially regulate bile acid synthesis in humanized mice. Hepatol Commun 2017;1:61-70. [PMID: 29404434 DOI: 10.1002/hep4.1020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
209 Giannelli V, Di Gregorio V, Iebba V, Giusto M, Schippa S, Merli M, Thalheimer U. Microbiota and the gut-liver axis: Bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol 2014; 20(45): 16795-16810 [PMID: 25492994 DOI: 10.3748/wjg.v20.i45.16795] [Cited by in CrossRef: 123] [Cited by in F6Publishing: 104] [Article Influence: 15.4] [Reference Citation Analysis]
210 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
211 Hatton GB, Ran S, Tranah TH, Shawcross DL. Lessons Learned from Faecal Microbiota Transplantation in Cirrhosis. Curr Hepatology Rep 2020;19:159-67. [DOI: 10.1007/s11901-020-00520-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
212 Li J, Rui J, Li Y, Tang N, Zhan S, Jiang J, Li X. Ambient temperature alters body size and gut microbiota of Xenopus tropicalis. Sci China Life Sci 2020;63:915-25. [PMID: 31686318 DOI: 10.1007/s11427-019-9540-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
213 Shamsaddini A, Gillevet PM, Acharya C, Fagan A, Gavis E, Sikaroodi M, McGeorge S, Khoruts A, Albhaisi S, Fuchs M, Sterling RK, Bajaj JS. Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis. Gastroenterology 2021;161:508-521.e7. [PMID: 33857456 DOI: 10.1053/j.gastro.2021.04.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
214 Reinert JP, Burnham K. Non-Lactulose Medication Therapies for the Management of Hepatic Encephalopathy: A Literature Review. J Pharm Pract 2021;34:922-33. [PMID: 32878558 DOI: 10.1177/0897190020953024] [Reference Citation Analysis]
215 Wang J, Wang Y, Zhang X, Liu J, Zhang Q, Zhao Y, Peng J, Feng Q, Dai J, Sun S. Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients. Front Microbiol. 2017;8:2222. [PMID: 29180991 DOI: 10.3389/fmicb.2017.02222] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 13.4] [Reference Citation Analysis]
216 Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol 2019;16:235-46. [DOI: 10.1038/s41575-018-0099-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 120] [Article Influence: 40.7] [Reference Citation Analysis]
217 Kalyana Chakravarthy S, Jayasudha R, Ranjith K, Dutta A, Pinna NK, Mande SS, Sharma S, Garg P, Murthy SI, Shivaji S. Alterations in the gut bacterial microbiome in fungal Keratitis patients. PLoS One 2018;13:e0199640. [PMID: 29933394 DOI: 10.1371/journal.pone.0199640] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
218 Bajaj JS, Vargas HE, Reddy KR, Lai JC, O'Leary JG, Tandon P, Wong F, Mitrani R, White MB, Kelly M, Fagan A, Patil R, Sait S, Sikaroodi M, Thacker LR, Gillevet PM. Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2019;17:756-765.e3. [PMID: 30036646 DOI: 10.1016/j.cgh.2018.07.022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
219 Jain V, Alexander EC, Burford C, Verma A, Dhawan A. Gut Microbiome: A Potential Modifiable Risk Factor in Biliary Atresia. J Pediatr Gastroenterol Nutr 2021;72:184-93. [PMID: 33427793 DOI: 10.1097/MPG.0000000000002973] [Reference Citation Analysis]
220 Albillos A, Martin-Mateos R, Van der Merwe S, Wiest R, Jalan R, Álvarez-Mon M. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34703031 DOI: 10.1038/s41575-021-00520-7] [Reference Citation Analysis]
221 Wang Y, Gao X, Zhang X, Xiao Y, Huang J, Yu D, Li X, Hu H, Ge T, Li D, Zhang T. Gut Microbiota Dysbiosis Is Associated with Altered Bile Acid Metabolism in Infantile Cholestasis. mSystems 2019;4:e00463-19. [PMID: 31848302 DOI: 10.1128/mSystems.00463-19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
222 Kajihara M, Koido S, Kanai T, Ito Z, Matsumoto Y, Takakura K, Saruta M, Kato K, Odamaki T, Xiao JZ, Sato N, Ohkusa T. Characterisation of blood microbiota in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2019;31:1577-1583. [PMID: 31441799 DOI: 10.1097/meg.0000000000001494] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
223 Úbeda M, Lario M, Muñoz L, Borrero MJ, Rodríguez-Serrano M, Sánchez-Díaz AM, Del Campo R, Lledó L, Pastor Ó, García-Bermejo L, Díaz D, Álvarez-Mon M, Albillos A. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol 2016;64:1049-57. [PMID: 26723896 DOI: 10.1016/j.jhep.2015.12.010] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 11.4] [Reference Citation Analysis]
224 Elsalem L, Jum'ah AA, Alfaqih MA, Aloudat O. The Bacterial Microbiota of Gastrointestinal Cancers: Role in Cancer Pathogenesis and Therapeutic Perspectives. Clin Exp Gastroenterol 2020;13:151-85. [PMID: 32440192 DOI: 10.2147/CEG.S243337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
225 Li JG, Wang CD, Tang ZH, Guo YQ, Zheng TC, Li YZ, You ZQ. The Gut Bacterial Community Composition of Wild Cervus albirostris (White-Lipped Deer) Detected by the 16S Ribosomal RNA Gene Sequencing. Curr Microbiol 2017;74:1100-7. [PMID: 28667467 DOI: 10.1007/s00284-017-1288-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
226 Bajaj JS, Moreau R, Kamath PS, Vargas HE, Arroyo V, Reddy KR, Szabo G, Tandon P, Olson J, Karvellas C, Gustot T, Lai JC, Wong F. Acute-on-Chronic Liver Failure: Getting Ready for Prime Time? Hepatology 2018;68:1621-32. [PMID: 29689120 DOI: 10.1002/hep.30056] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
227 Singhal R, Donde H, Ghare S, Stocke K, Zhang J, Vadhanam M, Reddy S, Gobejishvili L, Chilton P, Joshi-Barve S, Feng W, McClain C, Hoffman K, Petrosino J, Vital M, Barve S. Decrease in acetyl-CoA pathway utilizing butyrate-producing bacteria is a key pathogenic feature of alcohol-induced functional gut microbial dysbiosis and development of liver disease in mice. Gut Microbes 2021;13:1946367. [PMID: 34369304 DOI: 10.1080/19490976.2021.1946367] [Reference Citation Analysis]
228 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91. [PMID: 33268887 DOI: 10.1038/s41423-020-00579-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
229 Zhan S, Li N, Liu C, Mao R, Wu D, Li T, Chen M, Zhuang X, Zeng Z. Intestinal Fibrosis and Gut Microbiota: Clues From Other Organs. Front Microbiol 2021;12:694967. [PMID: 34335525 DOI: 10.3389/fmicb.2021.694967] [Reference Citation Analysis]
230 Yao X, Yu H, Fan G, Xiang H, Long L, Xu H, Wu Z, Chen M, Xi W, Gao Z, Liu C, Gong W, Yang A, Sun K, Yu R, Liang J, Xie B, Sun S. Impact of the Gut Microbiome on the Progression of Hepatitis B Virus Related Acute-on-Chronic Liver Failure. Front Cell Infect Microbiol 2021;11:573923. [PMID: 33889550 DOI: 10.3389/fcimb.2021.573923] [Reference Citation Analysis]
231 Li R, Mao Z, Ye X, Zuo T. Human Gut Microbiome and Liver Diseases: From Correlation to Causation. Microorganisms 2021;9:1017. [PMID: 34066850 DOI: 10.3390/microorganisms9051017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
232 Li F, Duan K, Wang C, McClain C, Feng W. Probiotics and Alcoholic Liver Disease: Treatment and Potential Mechanisms. Gastroenterol Res Pract 2016;2016:5491465. [PMID: 26839540 DOI: 10.1155/2016/5491465] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
233 Hasan LZ, Wu GY. Novel Agents in the Management of Hepatic Encephalopathy: A Review. J Clin Transl Hepatol 2021;9:749-59. [PMID: 34722190 DOI: 10.14218/JCTH.2021.00102] [Reference Citation Analysis]
234 Fernandez-Cantos MV, Garcia-Morena D, Iannone V, El-Nezami H, Kolehmainen M, Kuipers OP. Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD. Tissue Barriers 2021;:1879719. [PMID: 34280073 DOI: 10.1080/21688370.2021.1879719] [Reference Citation Analysis]
235 Iwasa M, Takei Y. Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia: Management of hepatic encephalopathy. Hepatol Res 2015;45:1155-62. [DOI: 10.1111/hepr.12495] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
236 Alimirah M, Sadiq O, Gordon SC. Novel Therapies in Hepatic Encephalopathy. Clin Liver Dis 2020;24:303-15. [PMID: 32245535 DOI: 10.1016/j.cld.2020.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Shen TD, Daniel SG, Patel S, Kaplan E, Phung L, Lemelle-Thomas K, Chau L, Herman L, Trisolini C, Stonelake A, Toal E, Khungar V, Bittinger K, Reddy KR, Wu GD. The Mucosally-Adherent Rectal Microbiota Contains Features Unique to Alcohol-Related Cirrhosis. Gut Microbes 2021;13:1987781. [PMID: 34747331 DOI: 10.1080/19490976.2021.1987781] [Reference Citation Analysis]
238 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
239 Gustot T, Stadlbauer V, Laleman W, Alessandria C, Thursz M. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. J Hepatol 2021;75 Suppl 1:S36-48. [PMID: 34039491 DOI: 10.1016/j.jhep.2020.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
240 Cresci GA. The gut microbiome: a new frontier for alcohol investigation. Alcohol Clin Exp Res 2015;39:947-9. [PMID: 25912525 DOI: 10.1111/acer.12732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
241 Ferreira MDF, Salavati Schmitz S, Schoenebeck JJ, Clements DN, Campbell SM, Gaylor DE, Mellanby RJ, Gow AG, Salavati M. Lactulose drives a reversible reduction and qualitative modulation of the faecal microbiota diversity in healthy dogs. Sci Rep 2019;9:13350. [PMID: 31527716 DOI: 10.1038/s41598-019-50090-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
242 Brown JJ, Mihaljevic JR, Des Marteaux L, Hrček J. Metacommunity theory for transmission of heritable symbionts within insect communities. Ecol Evol 2020;10:1703-21. [PMID: 32076545 DOI: 10.1002/ece3.5754] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
243 Jensen A, Ladegaard Grønkjær L, Holmstrup P, Vilstrup H, Kilian M. Unique subgingival microbiota associated with periodontitis in cirrhosis patients. Sci Rep 2018;8:10718. [PMID: 30013030 DOI: 10.1038/s41598-018-28905-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
244 Xia X, Chen J, Xia J, Wang B, Liu H, Yang L, Wang Y, Ling Z. Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. J Int Med Res 2018;46:3596-604. [PMID: 29806520 DOI: 10.1177/0300060518776064] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
245 Xu Y, Zha H, Chen W, Cao H, Li L. Recovery Dynamics of Intestinal Bacterial Communities of CCl4-Treated Mice with or without Mesenchymal Stem Cell Transplantation over Different Time Points. Biomed Res Int 2020;2020:1673602. [PMID: 33123564 DOI: 10.1155/2020/1673602] [Reference Citation Analysis]
246 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
247 Hussain SK, Dong TS, Agopian V, Pisegna JR, Durazo FA, Enayati P, Sundaram V, Benhammou JN, Noureddin M, Choi G, Ayoub WS, Lagishetty V, Elashoff D, Goodman MT, Jacobs JP. Dietary Protein, Fiber and Coffee Are Associated with Small Intestine Microbiome Composition and Diversity in Patients with Liver Cirrhosis. Nutrients 2020;12:E1395. [PMID: 32414035 DOI: 10.3390/nu12051395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
248 Sidhu GS, Go A, Attar BM, Mutneja HR, Arora S, Patel SA. Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review. BMJ Open Gastroenterol. 2017;4:e000154. [PMID: 28944070 DOI: 10.1136/bmjgast-2017-000154] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
249 Albhaisi S, Shamsaddini A, Fagan A, McGeorge S, Sikaroodi M, Gavis E, Patel S, Davis BC, Acharya C, Sterling RK, Matherly S, Fuchs M, Gillevet PM, Bajaj JS. Gut Microbial Signature of Hepatocellular Cancer in Men With Cirrhosis. Liver Transpl 2021;27:629-40. [PMID: 33492761 DOI: 10.1002/lt.25994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
250 Rocco A, Sgamato C, Compare D, Coccoli P, Nardone OM, Nardone G. Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives. Front Cell Dev Biol 2021;9:748253. [PMID: 34900994 DOI: 10.3389/fcell.2021.748253] [Reference Citation Analysis]
251 Horvath A, Rainer F, Bashir M, Leber B, Schmerboeck B, Klymiuk I, Groselj-Strele A, Durdevic M, Freedberg DE, Abrams JA, Fickert P, Stiegler P, Stadlbauer V. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. Sci Rep. 2019;9:12000. [PMID: 31427714 DOI: 10.1038/s41598-019-48352-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
252 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
253 Bajaj JS, Khoruts A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. Journal of Hepatology 2020;72:1003-27. [DOI: 10.1016/j.jhep.2020.01.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
254 Zha H, Chen Y, Wu J, Chang K, Lu Y, Zhang H, Xie J, Wang Q, Tang R, Li L. Characteristics of three microbial colonization states in the duodenum of the cirrhotic patients. Future Microbiol 2020;15:855-68. [PMID: 32662659 DOI: 10.2217/fmb-2019-0270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
255 Chen SH, Wan QS, Wang T, Zhang KH. Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis. Biomed Res Int 2020;2020:7170457. [PMID: 32280697 DOI: 10.1155/2020/7170457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Pei K, Ou J, Huang J, Ou S. p-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities. J Sci Food Agric. 2016;96:2952-2962. [PMID: 26692250 DOI: 10.1002/jsfa.7578] [Cited by in Crossref: 200] [Cited by in F6Publishing: 154] [Article Influence: 33.3] [Reference Citation Analysis]
257 Gong S, Ye T, Wang M, Wang M, Li Y, Ma L, Yang Y, Wang Y, Zhao X, Liu L, Yang M, Chen H, Qian J. Traditional Chinese Medicine Formula Kang Shuai Lao Pian Improves Obesity, Gut Dysbiosis, and Fecal Metabolic Disorders in High-Fat Diet-Fed Mice. Front Pharmacol 2020;11:297. [PMID: 32269525 DOI: 10.3389/fphar.2020.00297] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
258 Haraguchi M, Miuma S, Masumoto H, Ichikawa T, Kanda Y, Sasaki R, Fukushima M, Miyaaki H, Taura N, Nakao K. Bacteroides in colonic mucosa-associated microbiota affects the development of minimal hepatic encephalopathy in patients with cirrhosis. Hepatol Int 2019;13:482-9. [DOI: 10.1007/s12072-019-09963-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
259 Ding JH, Jin Z, Yang XX, Lou J, Shan WX, Hu YX, Du Q, Liao QS, Xie R, Xu JY. Role of gut microbiota via the gut-liver-brain axis in digestive diseases. World J Gastroenterol 2020; 26(40): 6141-6162 [PMID: 33177790 DOI: 10.3748/wjg.v26.i40.6141] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
260 Chen Y, Guo J, Qian G, Fang D, Shi D, Guo L, Li L. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol. 2015;30:1429-1437. [PMID: 25711972 DOI: 10.1111/jgh.12932] [Cited by in Crossref: 85] [Cited by in F6Publishing: 71] [Article Influence: 14.2] [Reference Citation Analysis]
261 Ballway JW, Song BJ. Translational Approaches with Antioxidant Phytochemicals against Alcohol-Mediated Oxidative Stress, Gut Dysbiosis, Intestinal Barrier Dysfunction, and Fatty Liver Disease. Antioxidants (Basel) 2021;10:384. [PMID: 33806556 DOI: 10.3390/antiox10030384] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
262 Bajaj JS, Fagan A, Sikaroodi M, White MB, Sterling RK, Gilles H, Heuman D, Stravitz RT, Matherly SC, Siddiqui MS, Puri P, Sanyal AJ, Luketic V, John B, Fuchs M, Ahluwalia V, Gillevet PM. Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. Liver Transpl. 2017;23:907-914. [PMID: 28240840 DOI: 10.1002/lt.24754] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
263 Philips CA, Phadke N, Ganesan K, Ranade S, Augustine P. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. Indian J Gastroenterol. 2018;37:215-225. [PMID: 29931479 DOI: 10.1007/s12664-018-0859-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
264 Lang S, Fairfied B, Gao B, Duan Y, Zhang X, Fouts DE, Schnabl B. Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients. Gut Microbes 2020;12:1785251. [PMID: 32684075 DOI: 10.1080/19490976.2020.1785251] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
265 Bajaj JS. Microbiome and complications of liver disease. Clin Liver Dis (Hoboken) 2015;5:96-9. [PMID: 31040960 DOI: 10.1002/cld.460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
266 Michelena J, Altamirano J, Abraldes JG, Affò S, Morales-Ibanez O, Sancho-Bru P, Dominguez M, García-Pagán JC, Fernández J, Arroyo V. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology. 2015;62:762-772. [PMID: 25761863 DOI: 10.1002/hep.27779] [Cited by in Crossref: 145] [Cited by in F6Publishing: 128] [Article Influence: 20.7] [Reference Citation Analysis]
267 Rackayová V, Flatt E, Braissant O, Grosse J, Capobianco D, Mastromarino P, McMillin M, DeMorrow S, McLin VA, Cudalbu C. Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease. Sci Rep 2021;11:2269. [PMID: 33500487 DOI: 10.1038/s41598-021-81871-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
268 Moratalla A, Ampuero J, Bellot P, Gallego-Durán R, Zapater P, Roger M, Figueruela B, Martínez-Moreno B, González-Navajas JM, Such J, Romero-Gómez M, Francés R. Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. Liver Int 2017;37:212-23. [PMID: 27388776 DOI: 10.1111/liv.13200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
269 Kriss M, Verna EC, Rosen HR, Lozupone CA. Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes. Transplantation 2019;103:668-78. [PMID: 30507741 DOI: 10.1097/TP.0000000000002568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
270 Macnaughtan J, Jalan R. Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis. Am J Gastroenterol. 2015;110:1399-1410; quiz 1411. [PMID: 26416191 DOI: 10.1038/ajg.2015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
271 Gupta H, Suk KT, Kim DJ. Gut Microbiota at the Intersection of Alcohol, Brain, and the Liver. J Clin Med 2021;10:541. [PMID: 33540624 DOI: 10.3390/jcm10030541] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
272 Xiong F, Wu SG, Zhang J, Jakovlić I, Li WX, Zou H, Li M, Wang GT. Dietary Bile Salt Types Influence the Composition of Biliary Bile Acids and Gut Microbiota in Grass Carp. Front Microbiol 2018;9:2209. [PMID: 30279683 DOI: 10.3389/fmicb.2018.02209] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
273 Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther. 2016;43 Suppl 1:11-26. [PMID: 26618922 DOI: 10.1111/apt.13435] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
274 El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TAE, Gomaa AI, Aly M, Mottawea W. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology (Basel) 2021;10:55. [PMID: 33451143 DOI: 10.3390/biology10010055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
275 Reeves HL, Zaki MYW, Day CP. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Dig Dis Sci 2016;61:1234-45. [DOI: 10.1007/s10620-016-4085-6] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 11.8] [Reference Citation Analysis]
276 Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology 2020;159:849-63. [PMID: 32569766 DOI: 10.1053/j.gastro.2020.04.077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
277 Ou JY, Huang JQ, Song Y, Yao SW, Peng XC, Wang MF, Ou SY. Feruloylated Oligosaccharides from Maize Bran Modulated the Gut Microbiota in Rats. Plant Foods Hum Nutr 2016;71:123-8. [PMID: 27165128 DOI: 10.1007/s11130-016-0547-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
278 Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Semin Liver Dis 2021;41:191-205. [PMID: 34107545 DOI: 10.1055/s-0041-1723752] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
279 Faust N, Yamada A, Haider H, Komaki Y, Komaki F, Micic D, Sakuraba A. Systemic review and network meta-analysis: Prophylactic antibiotic therapy for spontaneous bacterial peritonitis. World J Hepatol 2020; 12(5): 239-252 [PMID: 32547691 DOI: 10.4254/wjh.v12.i5.239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
280 Jin Y, Wu S, Zeng Z, Fu Z. Effects of environmental pollutants on gut microbiota. Environmental Pollution 2017;222:1-9. [DOI: 10.1016/j.envpol.2016.11.045] [Cited by in Crossref: 228] [Cited by in F6Publishing: 206] [Article Influence: 45.6] [Reference Citation Analysis]
281 Azhari H, Swain MG. Role of Peripheral Inflammation in Hepatic Encephalopathy. J Clin Exp Hepatol. 2018;8:281-285. [PMID: 30302045 DOI: 10.1016/j.jceh.2018.06.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
282 Jalan R, Yurdaydin C, Bajaj JS, Acharya SK, Arroyo V, Lin H, Gines P, Kim WR, Kamath PS. Toward an Improved Definition of Acute-on-Chronic Liver Failure. Gastroenterology 2014;147:4-10. [DOI: 10.1053/j.gastro.2014.05.005] [Cited by in Crossref: 165] [Cited by in F6Publishing: 140] [Article Influence: 20.6] [Reference Citation Analysis]
283 Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia. Adv Drug Deliv Rev 2015;90:55-68. [PMID: 25895618 DOI: 10.1016/j.addr.2015.04.009] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
284 Bajaj JS. The role of microbiota in hepatic encephalopathy. Gut Microbes. 2014;5:397-403. [PMID: 24690956 DOI: 10.4161/gmic.28684] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 10.8] [Reference Citation Analysis]
285 Ezzeldin S, El-Wazir A, Enany S, Muhammad A, Johar D, Osama A, Ahmed E, Shikshaky H, Magdeldin S. Current Understanding of Human Metaproteome Association and Modulation. J Proteome Res 2019;18:3539-54. [PMID: 31262181 DOI: 10.1021/acs.jproteome.9b00301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
286 Anty R, Tonohouan M, Ferrari-Panaia P, Piche T, Pariente A, Anstee QM, Gual P, Tran A. Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients. Clin Transl Gastroenterol. 2014;5:e56. [PMID: 24871371 DOI: 10.1038/ctg.2014.6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
287 Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases.Cell Mol Immunol. 2021;18:4-17. [PMID: 33318628 DOI: 10.1038/s41423-020-00592-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
288 Aitbaev KA, Murkamilov IT, Fomin VV. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation]. Ter Arkh 2017;89:120-8. [PMID: 28914862 DOI: 10.17116/terarkh2017898120-128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
289 Zha H, Fang DQ, van der Reis A, Chang K, Yang LY, Xie JJ, Shi D, Xu QM, Li YT, Li LJ. Vital members in the gut microbiotas altered by two probiotic Bifidobacterium strains against liver damage in rats. BMC Microbiol 2020;20:144. [PMID: 32503418 DOI: 10.1186/s12866-020-01827-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
290 Van der Merwe S, Chokshi S, Bernsmeier C, Albillos A. The multifactorial mechanisms of bacterial infection in decompensated cirrhosis. J Hepatol 2021;75 Suppl 1:S82-S100. [PMID: 34039494 DOI: 10.1016/j.jhep.2020.11.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
291 Wan X, Zhao H. New avenues to treatment of liver cirrhosis. Sci China Life Sci. 2014;57:1049-1050. [PMID: 25231841 DOI: 10.1007/s11427-014-4751-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
292 Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, Gmizic I, Stevanovic O, Djordjevic V, Lekic N, Russo E, Amedei A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int J Mol Sci. 2019;20:395. [PMID: 30658519 DOI: 10.3390/ijms20020395] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 27.3] [Reference Citation Analysis]
293 Ocvirk S, O'Keefe SJD. Dietary fat, bile acid metabolism and colorectal cancer. Semin Cancer Biol 2021;73:347-55. [PMID: 33069873 DOI: 10.1016/j.semcancer.2020.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
294 Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res. 2015;39:763-775. [PMID: 25872593 DOI: 10.1111/acer.12704] [Cited by in Crossref: 126] [Cited by in F6Publishing: 122] [Article Influence: 21.0] [Reference Citation Analysis]
295 Kornerup LS, Gluud LL, Vilstrup H, Dam G. Update on the Therapeutic Management of Hepatic Encephalopathy. Curr Gastroenterol Rep. 2018;20:21. [PMID: 29644492 DOI: 10.1007/s11894-018-0627-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
296 Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. Hepatology. 2018;. [PMID: 30289992 DOI: 10.1002/hep.30304] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 11.3] [Reference Citation Analysis]
297 Shalikiani NV, Bakulin IG, Dubinkina VB, Ishchenko DS, Alexeev DG, Tyakht AV, Pavlenko AV, Ilyina EN, Kostryukova ES, Taraskina AE, Skorodumova LO, Maev IV, Govorun VM. [Specific features of the enteric microbiota composition in patients with alcoholic liver cirrhosis]. Ter Arkh 2015;87:59-65. [PMID: 26978420 DOI: 10.17116/terarkh2015871259-65] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
298 Kanmani P, Suganya K, Kim H. The Gut Microbiota: How Does It Influence the Development and Progression of Liver Diseases.Biomedicines. 2020;8:501. [PMID: 33207562 DOI: 10.3390/biomedicines8110501] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
299 Acharya C, Betrapally NS, Gillevet PM, Sterling RK, Akbarali H, White MB, Ganapathy D, Fagan A, Sikaroodi M, Bajaj JS. Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:319-31. [DOI: 10.1111/apt.13858] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 12.2] [Reference Citation Analysis]
300 Li DK, Yan P, Abou-Samra AB, Chung RT, Butt AA. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES. Aliment Pharmacol Ther 2018;47:246-58. [PMID: 29105111 DOI: 10.1111/apt.14391] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
301 Liu A, Perumpail RB, Kumari R, Younossi ZM, Wong RJ, Ahmed A. Advances in cirrhosis: Optimizing the management of hepatic encephalopathy. World J Hepatol 2015; 7(29): 2871-2879 [PMID: 26692331 DOI: 10.4254/wjh.v7.i29.2871] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
302 Bartoletti M, Giannella M, Lewis RE, Viale P. Bloodstream infections in patients with liver cirrhosis. Virulence. 2016;7:309-319. [PMID: 26864729 DOI: 10.1080/21505594.2016.1141162] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
303 Bajaj JS, Kakiyama G, Savidge T, Takei H, Kassam ZA, Fagan A, Gavis EA, Pandak WM, Nittono H, Hylemon PB, Boonma P, Haag A, Heuman DM, Fuchs M, John B, Sikaroodi M, Gillevet PM. Antibiotic‐Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant. Hepatology 2018;68:1549-58. [DOI: 10.1002/hep.30037] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 14.5] [Reference Citation Analysis]
304 Jiang JW, Chen XH, Ren Z, Zheng SS. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis. Hepatobiliary Pancreat Dis Int 2019;18:19-27. [PMID: 30527903 DOI: 10.1016/j.hbpd.2018.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
305 Posteraro B, Paroni Sterbini F, Petito V, Rocca S, Cubeddu T, Graziani C, Arena V, Vassallo GA, Mosoni C, Lopetuso L, Lorrai I, Maccioni P, Masucci L, Martini C, Gasbarrini A, Sanguinetti M, Colombo G, Addolorato G. Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats. Alcohol Clin Exp Res 2018;42:2313-25. [PMID: 30320890 DOI: 10.1111/acer.13900] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
306 van Best N, Jansen PL, Rensen SS. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation. Hepatol Int. 2015;9:406-415. [PMID: 26067771 DOI: 10.1007/s12072-015-9640-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
307 Wilson A, McLean C, Kim RB. Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis. Curr Opin Lipidol 2016;27:148-54. [PMID: 26959704 DOI: 10.1097/MOL.0000000000000274] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
308 Liang Q, Zhang M, Hu Y, Zhang W, Zhu P, Chen Y, Xue P, Li Q, Wang K. Gut Microbiome Contributes to Liver Fibrosis Impact on T Cell Receptor Immune Repertoire. Front Microbiol 2020;11:571847. [PMID: 33329430 DOI: 10.3389/fmicb.2020.571847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
309 Howell J, Pinato DJ, Ramaswami R, Bettinger D, Arizumi T, Ferrari C, Yen C, Gibbin A, Burlone ME, Guaschino G, Sellers L, Black J, Pirisi M, Kudo M, Thimme R, Park J, Sharma R. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. Aliment Pharmacol Ther 2017;45:1146-55. [DOI: 10.1111/apt.13977] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
310 Amodio P, Canesso F, Montagnese S. Dietary management of hepatic encephalopathy revisited. Curr Opin Clin Nutr Metab Care. 2014;17:448-452. [PMID: 25025262 DOI: 10.1097/mco.0000000000000084] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
311 Liu N, Feng J, Lv Y, Liu Q, Deng J, Xia Y, Guo C, Zhou Y. Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study. Exp Ther Med 2019;18:4058-66. [PMID: 31611941 DOI: 10.3892/etm.2019.8011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
312 Trebicka J, Bork P, Krag A, Arumugam M. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol 2021;18:167-80. [PMID: 33257833 DOI: 10.1038/s41575-020-00376-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
313 Ponziani FR, Putignani L, Paroni Sterbini F, Petito V, Picca A, Del Chierico F, Reddel S, Calvani R, Marzetti E, Sanguinetti M, Gasbarrini A, Pompili M. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol Ther 2018;48:1301-11. [PMID: 30345704 DOI: 10.1111/apt.15004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
314 Lingiah VA, Pyrsopoulos NT. Bacterial Infections in Cirrhotic Patients in a Tertiary Care Hospital. J Clin Transl Hepatol 2021;9:32-9. [PMID: 33604253 DOI: 10.14218/JCTH.2020.00076] [Reference Citation Analysis]
315 Xu H, Wei Y, Ma H, Liu Y, Zhang Y, Hu L, Li J. Alterations of Gut Microbiome in the Patients With Severe Fever With Thrombocytopenia Syndrome. Front Microbiol 2018;9:2315. [PMID: 30327643 DOI: 10.3389/fmicb.2018.02315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
316 Hong M, Han DH, Hong J, Kim DJ, Suk KT. Are Probiotics Effective in Targeting Alcoholic Liver Diseases? Probiotics Antimicrob Proteins 2019;11:335-47. [PMID: 29687200 DOI: 10.1007/s12602-018-9419-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
317 Song HJ, Jeon N, Squires P. The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:1437-56. [PMID: 32548678 DOI: 10.1007/s00228-020-02927-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
318 Horvath A, Durdevic M, Leber B, di Vora K, Rainer F, Krones E, Douschan P, Spindelboeck W, Durchschein F, Zollner G, Stauber RE, Fickert P, Stiegler P, Stadlbauer V. Changes in the Intestinal Microbiome during a Multispecies Probiotic Intervention in Compensated Cirrhosis. Nutrients 2020;12:E1874. [PMID: 32585997 DOI: 10.3390/nu12061874] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
319 Hagerty SL, Ellingson JM, Hutchison KE. Biological Systems Are a Common Link Between Alcohol Use Disorder and Co-Occurring Psychiatric and Medical Conditions. Alcohol Clin Exp Res 2018;42:248-51. [PMID: 29197116 DOI: 10.1111/acer.13570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
320 Newman KL, Johnson KM, Cornia PB, Wu P, Itani K, Ioannou GN. Perioperative Evaluation and Management of Patients With Cirrhosis: Risk Assessment, Surgical Outcomes, and Future Directions. Clin Gastroenterol Hepatol 2020;18:2398-2414.e3. [PMID: 31376494 DOI: 10.1016/j.cgh.2019.07.051] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
321 Chen J, Wei Y, He J, Cui G, Zhu Y, Lu C, Ding Y, Xue R, Bai L, Uede T, Li L, Diao H. Natural killer T cells play a necessary role in modulating of immune-mediated liver injury by gut microbiota. Sci Rep 2014;4:7259. [PMID: 25435303 DOI: 10.1038/srep07259] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
322 Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight. 2017;2:e94416. [PMID: 28978799 DOI: 10.1172/jci.insight.94416] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 14.4] [Reference Citation Analysis]
323 Ticinesi A, Milani C, Lauretani F, Nouvenne A, Tana C, Ventura M, Meschi T. Gut Microbiome in the Elderly Hospitalized Patient. Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications. Elsevier; 2019. pp. 287-96. [DOI: 10.1016/b978-0-12-815249-2.00030-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
324 Bajaj JS. Altered Microbiota in Cirrhosis and Its Relationship to the Development of Infection. Clin Liver Dis (Hoboken) 2019;14:107-11. [PMID: 31632660 DOI: 10.1002/cld.827] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
325 Chaturvedi S, Rego A, Lucas LK, Gompert Z. Sources of Variation in the Gut Microbial Community of Lycaeides melissa Caterpillars. Sci Rep 2017;7:11335. [PMID: 28900218 DOI: 10.1038/s41598-017-11781-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
326 Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72:558-577. [PMID: 31622696 DOI: 10.1016/j.jhep.2019.10.003] [Cited by in Crossref: 141] [Cited by in F6Publishing: 151] [Article Influence: 47.0] [Reference Citation Analysis]
327 Lu H, Ren Z, Li A, Zhang H, Jiang J, Xu S, Luo Q, Zhou K, Sun X, Zheng S, Li L. Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma. Sci Rep. 2016;6:33142. [PMID: 27605161 DOI: 10.1038/srep33142] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 8.3] [Reference Citation Analysis]
328 Jin M, Kalainy S, Baskota N, Chiang D, Deehan EC, McDougall C, Tandon P, Martínez I, Cervera C, Walter J, Abraldes JG. Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids. Liver Int 2019;39:1437-47. [PMID: 30919578 DOI: 10.1111/liv.14106] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
329 Guohong-liu, Qingxi-zhao, Hongyun-wei. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. Annals of Hepatology 2019;18:796-803. [DOI: 10.1016/j.aohep.2019.06.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
330 Cassard AM, Ciocan D. Microbiota, a key player in alcoholic liver disease. Clin Mol Hepatol 2018;24:100-7. [PMID: 29268595 DOI: 10.3350/cmh.2017.0067] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
331 Gao W, Zhu Y, Ye J, Chu H. Gut non-bacterial microbiota contributing to alcohol-associated liver disease. Gut Microbes 2021;13:1984122. [PMID: 34711112 DOI: 10.1080/19490976.2021.1984122] [Reference Citation Analysis]
332 Pérez-Matute P, Oteo JA. Is it enough to eliminate hepatitis C virus to reverse the damage caused by the infection? World J Clin Infect Dis 2017; 7(1): 1-5 [DOI: 10.5495/wjcid.v7.i1.1] [Reference Citation Analysis]
333 Bajaj JS, Salzman NH, Acharya C, Sterling RK, White MB, Gavis EA, Fagan A, Hayward M, Holtz ML, Matherly S, Lee H, Osman M, Siddiqui MS, Fuchs M, Puri P, Sikaroodi M, Gillevet PM. Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. Hepatology. 2019;70:1690-1703. [PMID: 31038755 DOI: 10.1002/hep.30690] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 22.7] [Reference Citation Analysis]
334 Kuan YC, Huang KW, Lin CL, Luo JC, Kao CH. Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis. J Clin Med 2019;8:E1108. [PMID: 31349746 DOI: 10.3390/jcm8081108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
335 Glal KAM, Abd-Elsalam SM, Mostafa TM. Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial. J Hepatobiliary Pancreat Sci 2021. [PMID: 33768619 DOI: 10.1002/jhbp.947] [Reference Citation Analysis]
336 Wang T, Huang S, Wu C, Wang N, Zhang R, Wang M, Mao D. Intestinal Microbiota and Liver Diseases: Insights into Therapeutic Use of Traditional Chinese Medicine. Evid Based Complement Alternat Med 2021;2021:6682581. [PMID: 33976705 DOI: 10.1155/2021/6682581] [Reference Citation Analysis]
337 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
338 Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. Proton pump inhibitors: Risks of long-term use: Proton pump inhibitors. Journal of Gastroenterology and Hepatology 2017;32:1295-302. [DOI: 10.1111/jgh.13737] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 15.4] [Reference Citation Analysis]
339 Beraza N. Fibrosis and the intestinal microbiome; a focus on chronic liver disease. Curr Opin Pharmacol 2019;49:76-81. [PMID: 31670055 DOI: 10.1016/j.coph.2019.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
340 Miranda-Zazueta G, León-Garduño LAP, Aguirre-Valadez J, Torre-Delgadillo A. Bacterial infections in cirrhosis: Current treatment. Ann Hepatol 2020;19:238-44. [PMID: 32317149 DOI: 10.1016/j.aohep.2019.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
341 Li F, McClain CJ, Feng W. Microbiome dysbiosis and alcoholic liver disease. Liver Res 2019;3:218-26. [PMID: 33868760 DOI: 10.1016/j.livres.2019.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
342 Støy S, Laursen TL, Eriksen LL, Grønbæk H, Vilstrup H, Sandahl TD. No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation. Clin Transl Gastroenterol 2021;12:e00306. [PMID: 33566559 DOI: 10.14309/ctg.0000000000000306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
343 Liptak R, Gromova B, Gardlik R. Fecal Microbiota Transplantation as a Tool for Therapeutic Modulation of Non-gastrointestinal Disorders. Front Med (Lausanne) 2021;8:665520. [PMID: 34557498 DOI: 10.3389/fmed.2021.665520] [Reference Citation Analysis]
344 Sharpton SR, Yong GJM, Terrault NA, Lynch SV. Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:29-43. [PMID: 30619992 DOI: 10.1002/hep4.1284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
345 Kronsten VT, Shawcross DL. Hepatic encephalopathy and depression in chronic liver disease: is the common link systemic inflammation? Anal Biochem 2021;:114437. [PMID: 34715068 DOI: 10.1016/j.ab.2021.114437] [Reference Citation Analysis]
346 Bajaj JS, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, Unser A, Thacker LR, Sanyal AJ, Kang DJ, Sikaroodi M, Gillevet PM. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology. 2015;62:1260-1271. [PMID: 25820757 DOI: 10.1002/hep.27819] [Cited by in Crossref: 151] [Cited by in F6Publishing: 140] [Article Influence: 21.6] [Reference Citation Analysis]
347 Yang L, Li Y, Wang S, Bian X, Jiang X, Wu J, Wang K, Wang Q, Xia J, Jiang S, Zhuge A, Yuan Y, Li S, Li L. Western Diet Aggravated Carbon Tetrachloride-Induced Chronic Liver Injury by Disturbing Gut Microbiota and Bile Acid Metabolism. Mol Nutr Food Res 2021;65:e2000811. [PMID: 33458949 DOI: 10.1002/mnfr.202000811] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
348 Ikegami T, Honda A. Reciprocal interactions between bile acids and gut microbiota in human liver diseases: Bile acids and gut microbiota. Hepatol Res 2018;48:15-27. [DOI: 10.1111/hepr.13001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
349 Kang DJ, Betrapally NS, Ghosh SA, Sartor RB, Hylemon PB, Gillevet PM, Sanyal AJ, Heuman DM, Carl D, Zhou H, Liu R, Wang X, Yang J, Jiao C, Herzog J, Lippman HR, Sikaroodi M, Brown RR, Bajaj JS. Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice. Hepatology. 2016;64:1232-1248. [PMID: 27339732 DOI: 10.1002/hep.28696] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
350 Bajaj JS, Torre A, Rojas ML, Fagan A, Nandez IE, Gavis EA, De Leon Osorio O, White MB, Fuchs M, Sikaroodi M, Gillevet PM. Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico. Liver Int 2020;40:1395-407. [PMID: 32181561 DOI: 10.1111/liv.14437] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
351 Brown JM, Hazen SL. Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery. J Biol Chem 2017;292:8560-8. [PMID: 28389555 DOI: 10.1074/jbc.R116.765388] [Cited by in Crossref: 52] [Cited by in F6Publishing: 33] [Article Influence: 10.4] [Reference Citation Analysis]
352 Long KJ, Liu BW, Lu M, Feng RY, Han T, Xiang HL. Structure of intestinal microflora in hepatitis B cirrhosis patients and hepatitis B cirrhosis patients with diabetes mellitus. Shijie Huaren Xiaohua Zazhi 2018; 26(16): 986-992 [DOI: 10.11569/wcjd.v26.i16.986] [Reference Citation Analysis]
353 Yang L, Bian X, Wu W, Lv L, Li Y, Ye J, Jiang X, Wang Q, Shi D, Fang D, Wu J, Wang K, Wang Q, Xia J, Xie J, Lu Y, Li L. Protective effect of Lactobacillus salivarius Li01 on thioacetamide-induced acute liver injury and hyperammonaemia. Microb Biotechnol 2020;13:1860-76. [PMID: 32652882 DOI: 10.1111/1751-7915.13629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
354 Álvares-da-Silva MR, Oliveira CP, Fagan A, Longo L, Thoen RU, Yoshimura Zitelli PM, Tanaka Ferreira RM, Mcgeorge S, Shamsaddini A, Farias AQ, Sikaroodi M, Gillevet PM, Bajaj JS. Interaction of Microbiome, Diet, and Hospitalizations Between Brazilian and American Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00355-4. [PMID: 33813071 DOI: 10.1016/j.cgh.2021.03.045] [Reference Citation Analysis]
355 Kosnicki KL, Penprase JC, Cintora P, Torres PJ, Harris GL, Brasser SM, Kelley ST. Effects of moderate, voluntary ethanol consumption on the rat and human gut microbiome. Addict Biol 2019;24:617-30. [PMID: 29750384 DOI: 10.1111/adb.12626] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
356 Tranah TH, Edwards LA, Schnabl B, Shawcross DL. Targeting the gut-liver-immune axis to treat cirrhosis. Gut 2021;70:982-94. [PMID: 33060124 DOI: 10.1136/gutjnl-2020-320786] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
357 Bettinger D, Martin D, Rieg S, Schultheiss M, Buettner N, Thimme R, Boettler T. Treatment with proton pump inhibitors is associated with increased mortality in patients with pyogenic liver abscess. Aliment Pharmacol Ther 2018;47:801-8. [PMID: 29327781 DOI: 10.1111/apt.14512] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
358 Kriaa A, Bourgin M, Potiron A, Mkaouar H, Jablaoui A, Gérard P, Maguin E, Rhimi M. Microbial impact on cholesterol and bile acid metabolism: current status and future prospects. J Lipid Res 2019;60:323-32. [PMID: 30487175 DOI: 10.1194/jlr.R088989] [Cited by in Crossref: 57] [Cited by in F6Publishing: 34] [Article Influence: 14.3] [Reference Citation Analysis]
359 Reiberger T, Trebicka J. New liver - Fresh microbiome: Implications on brain function. Liver Transpl 2017;23:873-4. [PMID: 28509434 DOI: 10.1002/lt.24787] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
360 Cassano M, Dufour J. Inflammation and Microbiota Fingerprint: Delphi’s Oracle for Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma? Hepatology 2019;69:12-5. [DOI: 10.1002/hep.30267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
361 Davis BC, Bajaj JS. Effects of Alcohol on the Brain in Cirrhosis: Beyond Hepatic Encephalopathy. Alcohol Clin Exp Res. 2018;42:660-667. [PMID: 29417604 DOI: 10.1111/acer.13605] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
362 Gonzalez SA. Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis: Benefit or Risk? Am J Gastroenterol 2019;114:553-5. [DOI: 10.14309/ajg.0000000000000208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
363 Bajaj JS, Betrapally NS, Hylemon PB, Thacker LR, Daita K, Kang DJ, White MB, Unser AB, Fagan A, Gavis EA, Sikaroodi M, Dalmet S, Heuman DM, Gillevet PM. Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus. Sci Rep. 2015;5:18559. [PMID: 26692421 DOI: 10.1038/srep18559] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
364 Méndez-Sánchez N, Valencia-Rodriguez A, Vera-Barajas A, Abenavoli L, Scarpellini E, Ponciano-Rodriguez G, Wang DQ. The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer. Hepatoma Res 2020;6:5. [PMID: 32582865 DOI: 10.20517/2394-5079.2019.29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
365 Acharya C, Bajaj JS. Altered Microbiome in Patients With Cirrhosis and Complications. Clin Gastroenterol Hepatol 2019;17:307-21. [PMID: 30099098 DOI: 10.1016/j.cgh.2018.08.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
366 Zha H, Lu H, Wu J, Chang K, Wang Q, Zhang H, Li J, Luo Q, Lu Y, Li L. Vital Members in the More Dysbiotic Oropharyngeal Microbiotas in H7N9-Infected Patients. Front Med (Lausanne) 2020;7:396. [PMID: 32850904 DOI: 10.3389/fmed.2020.00396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
367 Piano S, Tonon M, Angeli P. Changes in the epidemiology and management of bacterial infections in cirrhosis. Clin Mol Hepatol 2021;27:437-45. [PMID: 33504138 DOI: 10.3350/cmh.2020.0329] [Reference Citation Analysis]
368 Martinsen TC, Fossmark R, Waldum HL. The Phylogeny and Biological Function of Gastric Juice-Microbiological Consequences of Removing Gastric Acid. Int J Mol Sci 2019;20:E6031. [PMID: 31795477 DOI: 10.3390/ijms20236031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
369 Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014;30:332-338. [PMID: 24625896 DOI: 10.1097/mog.0000000000000057] [Cited by in Crossref: 556] [Cited by in F6Publishing: 326] [Article Influence: 69.5] [Reference Citation Analysis]
370 Phelan JP, Reen FJ, Caparros-Martin JA, O'Connor R, O'Gara F. Rethinking the bile acid/gut microbiome axis in cancer. Oncotarget 2017;8:115736-47. [PMID: 29383197 DOI: 10.18632/oncotarget.22803] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
371 Preveden T, Scarpellini E, Milić N, Luzza F, Abenavoli L. Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2017;11:813-9. [PMID: 28621554 DOI: 10.1080/17474124.2017.1343663] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 8.4] [Reference Citation Analysis]
372 Rai R, Saraswat VA, Dhiman RK. Gut microbiota: its role in hepatic encephalopathy. J Clin Exp Hepatol. 2015;5:S29-S36. [PMID: 26041954 DOI: 10.1016/j.jceh.2014.12.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 9.5] [Reference Citation Analysis]
373 Zhang B, Wu X, Song Q, Ning A, Liang J, Song L, Liu J, Zhang Y, Yuan D, Sun X, Wu Z. Gut Microbiota Modulates Intestinal Pathological Injury in Schistosoma japonicum-Infected Mice. Front Med (Lausanne) 2020;7:588928. [PMID: 33313045 DOI: 10.3389/fmed.2020.588928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
374 Liu Q, Li F, Zhuang Y, Xu J, Wang J, Mao X, Zhang Y, Liu X. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. Gut Pathog. 2019;11:1. [PMID: 30675188 DOI: 10.1186/s13099-018-0281-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
375 Wei S, Bahl MI, Baunwall SMD, Hvas CL, Licht TR. Determining Gut Microbial Dysbiosis: a Review of Applied Indexes for Assessment of Intestinal Microbiota Imbalances. Appl Environ Microbiol 2021;87:e00395-21. [PMID: 33741632 DOI: 10.1128/AEM.00395-21] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
376 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
377 Samji NS, Heda R, Kovalic AJ, Satapathy SK. Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis. Gastroenterology Clinics of North America 2020;49:151-64. [DOI: 10.1016/j.gtc.2019.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
378 Bajaj JS, Acharya C, Sikaroodi M, Gillevet PM, Thacker LR. Cost-effectiveness of integrating gut microbiota analysis into hospitalisation prediction in cirrhosis. GastroHep 2020;2:79-86. [PMID: 33071650 DOI: 10.1002/ygh2.390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
379 Kwong EK, Liu R, Zhao D, Li X, Zhu W, Wang X, Gurley EC, Lai G, Liu J, Hylemon PB, Zhou H. The role of sphingosine kinase 2 in alcoholic liver disease. Dig Liver Dis 2019;51:1154-63. [PMID: 31003959 DOI: 10.1016/j.dld.2019.03.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
380 Kakiyama G, Hylemon PB, Zhou H, Pandak WM, Heuman DM, Kang DJ, Takei H, Nittono H, Ridlon JM, Fuchs M. Colonic inflammation and secondary bile acids in alcoholic cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2014;306:G929-G937. [PMID: 24699327 DOI: 10.1152/ajpgi.00315.2013] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 11.4] [Reference Citation Analysis]
381 Mancini A, Campagna F, Amodio P, Tuohy KM. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. Food Funct. 2018;9:1373-1388. [PMID: 29485654 DOI: 10.1039/c7fo01528c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
382 Bajaj JS, Reddy KR, O'Leary JG, Vargas HE, Lai JC, Kamath PS, Tandon P, Wong F, Subramanian RM, Thuluvath P, Fagan A, White MB, Gavis EA, Sehrawat T, de la Rosa Rodriguez R, Thacker LR, Sikaroodi M, Garcia-Tsao G, Gillevet PM. Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. Gastroenterology 2020;159:1715-1730.e12. [PMID: 32687928 DOI: 10.1053/j.gastro.2020.07.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
383 Bajaj JS, Idilman R, Mabudian L, Hood M, Fagan A, Turan D, White MB, Karakaya F, Wang J, Atalay R, Hylemon PB, Gavis EA, Brown R, Thacker LR, Acharya C, Heuman DM, Sikaroodi M, Gillevet PM. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. Hepatology 2018;68:234-47. [DOI: 10.1002/hep.29791] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
384 Petagine L, Zariwala MG, Patel VB. Alcoholic liver disease: Current insights into cellular mechanisms. World J Biol Chem 2021; 12(5): 87-103 [PMID: 34630912 DOI: 10.4331/wjbc.v12.i5.87] [Reference Citation Analysis]
385 Vaughn BP, Rank KM, Khoruts A. Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease. Clin Gastroenterol Hepatol. 2019;17:353-361. [PMID: 30055267 DOI: 10.1016/j.cgh.2018.07.026] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
386 Gao X, Wang F, Zhao P, Zhang R, Zeng Q. Effect of heat-killed Streptococcus thermophilus on type 2 diabetes rats. PeerJ 2019;7:e7117. [PMID: 31223540 DOI: 10.7717/peerj.7117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
387 Ponziani FR, Gerardi V, Pecere S, D’Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 2015; 21(43): 12322-12333 [PMID: 26604640 DOI: 10.3748/wjg.v21.i43.12322] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
388 Wellhöner F, Döscher N, Tergast TL, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Maasoumy B, Wedemeyer H, Cornberg M, Pieper DH, Heidrich B. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. Scand J Gastroenterol 2019;54:1033-41. [PMID: 31361979 DOI: 10.1080/00365521.2019.1647280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
389 Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Probiotics in hepatology: An update. World J Hepatol 2021; 13(9): 1154-1166 [PMID: 34630882 DOI: 10.4254/wjh.v13.i9.1154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
390 Bajaj JS, Kakiyama G, Cox IJ, Nittono H, Takei H, White M, Fagan A, Gavis EA, Heuman DM, Gilles HC, Hylemon P, Taylor-Robinson SD, Legido-Quigley C, Kim M, Xu J, Williams R, Sikaroodi M, Pandak WM, Gillevet PM. Alterations in gut microbial function following liver transplant. Liver Transpl 2018;24:752-61. [PMID: 29500907 DOI: 10.1002/lt.25046] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
391 Mullish BH, McDonald JAK, Thursz MR, Marchesi JR. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology 2017;66:1354-5. [PMID: 28714089 DOI: 10.1002/hep.29369] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
392 Rosenblatt R, Mehta A, Cohen‐mekelburg S, Shen N, Snell D, Lucero C, Jesudian A, Fortune B, Crawford CV, Kumar S. The rise of Clostridioides difficile infections and fall of associated mortality in hospitalized advanced cirrhotics. Liver Int 2019;39:1263-70. [DOI: 10.1111/liv.14077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
393 Vasco M, Paolillo R, Schiano C, Sommese L, Cuomo O, Napoli C. Compromised nutritional status in patients with end-stage liver disease: Role of gut microbiota. Hepatobiliary Pancreat Dis Int 2018;17:290-300. [PMID: 30173786 DOI: 10.1016/j.hbpd.2018.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
394 Zhang L, Wu Y, Chen T, Ren C, Li X, Liu G. Relationship between intestinal microbial dysbiosis and primary liver cancer. Hepatobiliary & Pancreatic Diseases International 2019;18:149-57. [DOI: 10.1016/j.hbpd.2019.01.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
395 Cassard AM, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr 2017;5. [PMID: 28840806 DOI: 10.1128/microbiolspec.BAD-0007-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
396 Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2018;15:753-64. [DOI: 10.1038/s41575-018-0045-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
397 Gu Z, Wu Y, Wang Y, Sun H, You Y, Piao C, Liu J. Lactobacillus rhamnosus Granules Dose-Dependently Balance Intestinal Microbiome Disorders and Ameliorate Chronic Alcohol-Induced Liver Injury.J Med Food. 2020;23:114-124. [PMID: 31747353 DOI: 10.1089/jmf.2018.4357] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
398 Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol 2021;75 Suppl 1:S67-81. [PMID: 34039493 DOI: 10.1016/j.jhep.2020.11.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
399 Piacentino D, Grant-Beurmann S, Vizioli C, Li X, Moore CF, Ruiz-Rodado V, Lee MR, Joseph PV, Fraser CM, Weerts EM, Leggio L. Gut microbiome and metabolome in a non-human primate model of chronic excessive alcohol drinking. Transl Psychiatry 2021;11:609. [PMID: 34853299 DOI: 10.1038/s41398-021-01728-6] [Reference Citation Analysis]
400 Shang Q, Shan X, Cai C, Hao J, Li G, Yu G. Dietary fucoidan modulates the gut microbiota in mice by increasing the abundance of Lactobacillus and Ruminococcaceae. Food Funct 2016;7:3224-32. [DOI: 10.1039/c6fo00309e] [Cited by in Crossref: 141] [Cited by in F6Publishing: 55] [Article Influence: 23.5] [Reference Citation Analysis]
401 Ocvirk S, Wilson AS, Posma JM, Li JV, Koller KR, Day GM, Flanagan CA, Otto JE, Sacco PE, Sacco FD, Sapp FR, Wilson AS, Newton K, Brouard F, DeLany JP, Behnning M, Appolonia CN, Soni D, Bhatti F, Methé B, Fitch A, Morris A, Gaskins HR, Kinross J, Nicholson JK, Thomas TK, O'Keefe SJD. A prospective cohort analysis of gut microbial co-metabolism in Alaska Native and rural African people at high and low risk of colorectal cancer. Am J Clin Nutr 2020;111:406-19. [PMID: 31851298 DOI: 10.1093/ajcn/nqz301] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
402 Aguirre Valadez JM, Rivera-Espinosa L, Méndez-Guerrero O, Chávez-Pacheco JL, García Juárez I, Torre A. Intestinal permeability in a patient with liver cirrhosis. Ther Clin Risk Manag 2016;12:1729-48. [PMID: 27920543 DOI: 10.2147/TCRM.S115902] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
403 Acharya C, Bajaj JS. Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46:155-169. [PMID: 28164848 DOI: 10.1016/j.gtc.2016.09.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
404 Patidar KR, Xu C, Shamseddeen H, Cheng YW, Ghabril MS, Mukthinuthalapati VVPK, Fricker ZP, Akinyeye S, Nephew LD, Desai AP, Anderson M, El-Achkar TM, Chalasani NP, Orman ES. Development and Validation of a Model to Predict Acute Kidney Injury in Hospitalized Patients With Cirrhosis. Clin Transl Gastroenterol 2019;10:e00075. [PMID: 31478958 DOI: 10.14309/ctg.0000000000000075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
405 Shek D, Chen D, Read SA, Ahlenstiel G. Examining the gut-liver axis in liver cancer using organoid models. Cancer Lett 2021;510:48-58. [PMID: 33891996 DOI: 10.1016/j.canlet.2021.04.008] [Reference Citation Analysis]
406 Hartmann P, Chu H, Duan Y, Schnabl B. Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. Am J Physiol Gastrointest Liver Physiol 2019;316:G563-73. [PMID: 30767680 DOI: 10.1152/ajpgi.00370.2018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
407 Betrapally NS, Gillevet PM, Bajaj JS. Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects? Gastroenterology 2016;150:1745-1755.e3. [PMID: 26948887 DOI: 10.1053/j.gastro.2016.02.073] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 12.2] [Reference Citation Analysis]
408 Sarin SK, Pande A, Schnabl B. Microbiome as a therapeutic target in alcohol-related liver disease. Journal of Hepatology 2019;70:260-72. [DOI: 10.1016/j.jhep.2018.10.019] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 23.3] [Reference Citation Analysis]
409 Jindal A, Rastogi A, Sarin SK. Reviewing the diagnostic criteria for acute-on-chronic liver failure. Expert Rev Gastroenterol Hepatol 2016;10:1385-95. [PMID: 27771965 DOI: 10.1080/17474124.2016.1250622] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
410 Milosevic I, Russo E, Vujovic A, Barac A, Stevanovic O, Gitto S, Amedei A. Microbiota and viral hepatitis: State of the art of a complex matter. World J Gastroenterol 2021; 27(33): 5488-5501 [PMID: 34588747 DOI: 10.3748/wjg.v27.i33.5488] [Reference Citation Analysis]
411 Adams LA, Wang Z, Liddle C, Melton PE, Ariff A, Chandraratna H, Tan J, Ching H, Coulter S, de Boer B, Christophersen CT, O'Sullivan TA, Morrison M, Jeffrey GP. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2020;40:1356-65. [PMID: 32243703 DOI: 10.1111/liv.14453] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
412 Lee PC, Hsieh YC, Huo TI, Yang UC, Lin CH, Li CP, Huang YH, Hou MC, Lin HC, Lee KC. Active Vitamin D3 Treatment Attenuated Bacterial Translocation via Improving Intestinal Barriers in Cirrhotic Rats. Mol Nutr Food Res 2021;65:e2000937. [PMID: 33258263 DOI: 10.1002/mnfr.202000937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
413 Jun T, Ozbek U, Dharmapuri S, Hardy-Abeloos C, Zhu H, Lin JY, Personeni N, Pressiani T, Nishida N, Lee PC, Lee CJ, Hildebrand H, Nimkar N, Paul S, Fessas P, Naeem M, Bettinger D, Khan U, Saeed A, Huang YH, Kudo M, Rimassa L, Marron TU, Pinato DJ, Ang C. Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol 2021;13:17588359211010937. [PMID: 33995594 DOI: 10.1177/17588359211010937] [Reference Citation Analysis]
414 Llopis M, Cassard AM, Wrzosek L, Boschat L, Bruneau A, Ferrere G, Puchois V, Martin JC, Lepage P, Le Roy T, Lefèvre L, Langelier B, Cailleux F, González-castro AM, Rabot S, Gaudin F, Agostini H, Prévot S, Berrebi D, Ciocan D, Jousse C, Naveau S, Gérard P, Perlemuter G. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 2016;65:830-9. [DOI: 10.1136/gutjnl-2015-310585] [Cited by in Crossref: 230] [Cited by in F6Publishing: 214] [Article Influence: 32.9] [Reference Citation Analysis]
415 Shalimar. Gut microbiome and liver diseases. J Clin Exp Hepatol 2014;4:267-8. [PMID: 25755571 DOI: 10.1016/j.jceh.2014.08.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
416 Mordant A, Kleiner M. Evaluation of Sample Preservation and Storage Methods for Metaproteomics Analysis of Intestinal Microbiomes. Microbiol Spectr 2021;9:e0187721. [PMID: 34908431 DOI: 10.1128/Spectrum.01877-21] [Reference Citation Analysis]
417 Arab JP, Arrese M, Shah VH. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives. Hepatol Res 2020;50:407-18. [PMID: 31840358 DOI: 10.1111/hepr.13473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
418 Santiago A, Pozuelo M, Poca M, Gely C, Nieto JC, Torras X, Román E, Campos D, Sarrabayrouse G, Vidal S, Alvarado-Tapias E, Guarner F, Soriano G, Manichanh C, Guarner C. Alteration of the serum microbiome composition in cirrhotic patients with ascites. Sci Rep 2016;6:25001. [PMID: 27112233 DOI: 10.1038/srep25001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
419 Brown ZJ, Heinrich B, Greten TF. Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nat Rev Gastroenterol Hepatol 2018;15:536-54. [DOI: 10.1038/s41575-018-0033-6] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 17.5] [Reference Citation Analysis]
420 Kang DJ, Kakiyama G, Betrapally NS, Herzog J, Nittono H, Hylemon PB, Zhou H, Carroll I, Yang J, Gillevet PM, Jiao C, Takei H, Pandak WM, Iida T, Heuman DM, Fan S, Fiehn O, Kurosawa T, Sikaroodi M, Sartor RB, Bajaj JS. Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition. Clin Transl Gastroenterol 2016;7:e187. [PMID: 27560928 DOI: 10.1038/ctg.2016.44] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
421 Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact. Int J Mol Sci 2021;22:1917. [PMID: 33671926 DOI: 10.3390/ijms22041917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
422 Bian X, Wu W, Yang L, Lv L, Wang Q, Li Y, Ye J, Fang D, Wu J, Jiang X, Shi D, Li L. Administration of Akkermansia muciniphila Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. Front Microbiol 2019;10:2259. [PMID: 31632373 DOI: 10.3389/fmicb.2019.02259] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 27.3] [Reference Citation Analysis]
423 Mendes BG, Schnabl B. From intestinal dysbiosis to alcohol-associated liver disease. Clin Mol Hepatol 2020;26:595-605. [PMID: 32911590 DOI: 10.3350/cmh.2020.0086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
424 Chong PP, Koh AY. The gut microbiota in transplant patients. Blood Rev 2020;39:100614. [PMID: 31492463 DOI: 10.1016/j.blre.2019.100614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
425 Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017;5:138-147. [PMID: 28533911 DOI: 10.1093/gastro/gox013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
426 Patel VC, White H, Støy S, Bajaj JS, Shawcross DL. Clinical science workshop: targeting the gut-liver-brain axis. Metab Brain Dis 2016;31:1327-37. [PMID: 26446022 DOI: 10.1007/s11011-015-9743-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
427 Kronsten VT, Tranah TH, Pariante C, Shawcross DL. Gut-derived systemic inflammation as a driver of depression in chronic liver disease. J Hepatol 2021:S0168-8278(21)02180-2. [PMID: 34800610 DOI: 10.1016/j.jhep.2021.11.008] [Reference Citation Analysis]
428 Lamatsch S, Sittner R, Tacke F, Engelmann C. Novel drug discovery strategies for the treatment of decompensated cirrhosis. Expert Opin Drug Discov 2021;:1-10. [PMID: 34971342 DOI: 10.1080/17460441.2022.2020755] [Reference Citation Analysis]
429 Hassouneh R, Bajaj JS. Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment. J Clin Med 2021;10:330. [PMID: 33477417 DOI: 10.3390/jcm10020330] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
430 Yu S, Xiong Y, Xu J, Liang X, Fu Y, Liu D, Yu X, Wu D. Identification of Dysfunctional Gut Microbiota Through Rectal Swab in Patients with Different Severity of Acute Pancreatitis. Dig Dis Sci. 2020;65:3223-3237. [PMID: 32076933 DOI: 10.1007/s10620-020-06061-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
431 Traub J, Reiss L, Aliwa B, Stadlbauer V. Malnutrition in Patients with Liver Cirrhosis. Nutrients 2021;13:540. [PMID: 33562292 DOI: 10.3390/nu13020540] [Reference Citation Analysis]
432 Heath RD, Cockerell C, Mankoo R, Ibdah JA, Tahan V. Fecal microbiota transplantation and its potential therapeutic uses in gastrointestinal disorders. North Clin Istanb. 2018;5:79-88. [PMID: 29607440 DOI: 10.14744/nci.2017.10692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
433 Oikonomou T, Papatheodoridis GV, Samarkos M, Goulis I, Cholongitas E. Clinical impact of microbiome in patients with decompensated cirrhosis. World J Gastroenterol 2018; 24(34): 3813-3820 [PMID: 30228776 DOI: 10.3748/wjg.v24.i34.3813] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
434 Singanayagam A, Triantafyllou E. Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting. Front Immunol 2021;12:661182. [PMID: 33868313 DOI: 10.3389/fimmu.2021.661182] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
435 Claus SP, Guillou H, Ellero-Simatos S. The gut microbiota: a major player in the toxicity of environmental pollutants? NPJ Biofilms Microbiomes. 2016;2:16003. [PMID: 28721242 DOI: 10.1038/npjbiofilms.2016.3] [Cited by in Crossref: 246] [Cited by in F6Publishing: 216] [Article Influence: 41.0] [Reference Citation Analysis]
436 Bajaj JS, OʼLeary JG, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, Biggins SW, Lai JC, Vargas HE, Maliakkal B, Fallon MB, Thuluvath PJ, Subramanian RM, Thacker LR, Reddy KR. Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. Am J Gastroenterol 2019;114:1091-100. [PMID: 31180922 DOI: 10.14309/ajg.0000000000000280] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
437 Quintanilla-Mena M, Vega-Arreguin J, Del Río-García M, Patiño-Suárez V, Peraza-Echeverria S, Puch-Hau C. The effect of benzo[a]pyrene on the gut microbiota of Nile tilapia (Oreochromis niloticus). Appl Microbiol Biotechnol 2021;105:7935-47. [PMID: 34542683 DOI: 10.1007/s00253-021-11592-5] [Reference Citation Analysis]
438 Shawcross DL. Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy? Expert Rev Gastroenterol Hepatol. 2015;9:539-542. [PMID: 25846450 DOI: 10.1586/17474124.2015.1035257] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
439 Ponziani FR, Zocco MA, Cerrito L, Gasbarrini A, Pompili M. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol. 2018;12:641-656. [PMID: 29806487 DOI: 10.1080/17474124.2018.1481747] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 10.5] [Reference Citation Analysis]
440 Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs LP, Ma L, Roy S, Fu Q, Brown ZJ, Wabitsch S, Thovarai V, Fu J, Feng D, Ruf B, Cui LL, Subramanyam V, Frank KM, Wang S, Kleiner DE, Ritz T, Rupp C, Gao B, Longerich T, Kroemer A, Wang XW, Ruchirawat M, Korangy F, Schnabl B, Trinchieri G, Greten TF. Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. Cancer Discov 2021;11:1248-67. [PMID: 33323397 DOI: 10.1158/2159-8290.CD-20-0304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
441 Norvell JP. Spotlight on Impactful Research: Impact of Liver Transplantation on Gut Microbiota and Cognitive Function. Clin Liver Dis (Hoboken) 2019;13:72-3. [PMID: 30988940 DOI: 10.1002/cld.746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
442 Patel VC, Shawcross DL. Salivary microbiota-immune profiling in cirrhosis: could this be the noninvasive strategy that will revolutionize prognostication in hepatology? Hepatology. 2015;62:1001-1003. [PMID: 25998053 DOI: 10.1002/hep.27870] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
443 Hung T, Lee H, Tseng C, Tsai C, Tsai C. Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding. Clinics and Research in Hepatology and Gastroenterology 2018;42:353-9. [DOI: 10.1016/j.clinre.2017.11.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
444 Zhang T, Zhang S, Jin C, Lin Z, Deng T, Xie X, Deng L, Li X, Ma J, Ding X, Liu Y, Shan Y, Yu Z, Wang Y, Chen G, Li J. A Predictive Model Based on the Gut Microbiota Improves the Diagnostic Effect in Patients With Cholangiocarcinoma. Front Cell Infect Microbiol 2021;11:751795. [PMID: 34888258 DOI: 10.3389/fcimb.2021.751795] [Reference Citation Analysis]
445 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
446 Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25:1054-1062.e5. [PMID: 28467925 DOI: 10.1016/j.cmet.2017.04.001] [Cited by in Crossref: 349] [Cited by in F6Publishing: 334] [Article Influence: 87.3] [Reference Citation Analysis]
447 Piano S, Angeli P. Bacterial Infections in Cirrhosis as a Cause or Consequence of Decompensation? Clin Liver Dis 2021;25:357-72. [PMID: 33838855 DOI: 10.1016/j.cld.2021.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
448 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
449 Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H. Management of refractory cirrhotic ascites: challenges and solutions. Hepat Med. 2018;10:55-71. [PMID: 30013405 DOI: 10.2147/hmer.s136578] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
450 Liu R, Kang JD, Sartor RB, Sikaroodi M, Fagan A, Gavis EA, Zhou H, Hylemon PB, Herzog JW, Li X, Lippman RH, Gonzalez-Maeso J, Wade JB, Ghosh S, Gurley E, Gillevet PM, Bajaj JS. Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant. Hepatology 2020;71:611-26. [PMID: 31220352 DOI: 10.1002/hep.30827] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
451 Zhong W, Zhou Z. Sealing the Leaky Gut Represents a Beneficial Mechanism of Zinc Intervention for Alcoholic Liver Disease. Dietary Interventions in Gastrointestinal Diseases. Elsevier; 2019. pp. 91-106. [DOI: 10.1016/b978-0-12-814468-8.00008-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
452 Adolph TE, Grander C, Moschen AR, Tilg H. Liver–Microbiome Axis in Health and Disease. Trends in Immunology 2018;39:712-23. [DOI: 10.1016/j.it.2018.05.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 14.3] [Reference Citation Analysis]
453 Santiago A, Sanchez E, Clark A, Pozuelo M, Calvo M, Yañez F, Sarrabayrouse G, Perea L, Vidal S, Gallardo A, Guarner C, Soriano G, Manichanh C. Sequential Changes in the Mesenteric Lymph Node Microbiome and Immune Response during Cirrhosis Induction in Rats. mSystems 2019;4:e00278-18. [PMID: 30801032 DOI: 10.1128/mSystems.00278-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
454 Kerbert AJC, Jalan R. Recent advances in understanding and managing hepatic encephalopathy in chronic liver disease. F1000Res 2020;9:F1000 Faculty Rev-312. [PMID: 32399191 DOI: 10.12688/f1000research.22183.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
455 Rossen NG, Fuentes S, Boonstra K, D'Haens GR, Heilig HG, Zoetendal EG, de Vos WM, Ponsioen CY. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis. 2015;9:342-348. [PMID: 25547975 DOI: 10.1093/ecco-jcc/jju023] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 8.3] [Reference Citation Analysis]
456 Ponziani FR, Valenza V, Nure E, Bianco G, Marrone G, Grieco A, Pompili M, Gasbarrini A, Agnes S, Sganga G. Effect of liver transplantation on intestinal permeability and correlation with infection episodes. PLoS One 2020;15:e0235359. [PMID: 32589654 DOI: 10.1371/journal.pone.0235359] [Reference Citation Analysis]
457 Fukui H. Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms. 2015;3:759-791. [PMID: 27682116 DOI: 10.3390/microorganisms3040759] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
458 Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol 2017; 23(47): 8355-8366 [PMID: 29307995 DOI: 10.3748/wjg.v23.i47.8355] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
459 Wu W, Lv L, Shi D, Ye J, Fang D, Guo F, Li Y, He X, Li L. Protective Effect of Akkermansia muciniphila against Immune-Mediated Liver Injury in a Mouse Model. Front Microbiol. 2017;8:1804. [PMID: 29033903 DOI: 10.3389/fmicb.2017.01804] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 14.2] [Reference Citation Analysis]
460 Sanduzzi Zamparelli M, Rocco A, Compare D, Nardone G. The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma. United European Gastroenterol J. 2017;5:944-953. [PMID: 29163959 DOI: 10.1177/2050640617705576] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
461 Okura Y, Namisaki T, Sato S, Moriya K, Akahane T, Kitade M, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Seki K, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Kaya D, Tsuji Y, Ozutsumi T, Kitagawa K, Mashitani T, Ogawa H, Ishida K, Mitoro A, Yamao J, Yoshiji H. Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. Hepatol Res 2019;49:232-8. [PMID: 30198141 DOI: 10.1111/hepr.13249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
462 Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, Vilstrup H, Jalan R. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73:1526-1547. [PMID: 33097308 DOI: 10.1016/j.jhep.2020.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
463 Zhang ZL, Duan ZJ. Gut-liver axis: An important target for prevention and treatment of liver diseases. Shijie Huaren Xiaohua Zazhi 2016; 24(23): 3454-3460 [DOI: 10.11569/wcjd.v24.i23.3454] [Reference Citation Analysis]
464 Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020;9:E875. [PMID: 32260126 DOI: 10.3390/cells9040875] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 24.5] [Reference Citation Analysis]
465 An L, Wirth U, Koch D, Schirren M, Drefs M, Koliogiannis D, Nieß H, Andrassy J, Guba M, Bazhin AV, Werner J, Kühn F. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. J Gastrointest Surg 2021. [PMID: 34734369 DOI: 10.1007/s11605-021-05188-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
466 Liu Y, Li J, Jin Y, Zhao L, Zhao F, Feng J, Li A, Wei Y. Splenectomy Leads to Amelioration of Altered Gut Microbiota and Metabolome in Liver Cirrhosis Patients. Front Microbiol. 2018;9:963. [PMID: 29867867 DOI: 10.3389/fmicb.2018.00963] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
467 Bajaj JS, Fagan A, Sikaroodi M, Kakiyama G, Takei H, Degefu Y, Pandak WM, Hylemon PB, Fuchs M, John B, Heuman DM, Gavis E, Nittono H, Patil R, Gillevet PM. Alterations in Skin Microbiomes of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2019;17:2581-2591.e15. [PMID: 30905718 DOI: 10.1016/j.cgh.2019.03.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
468 Zha H, Liu F, Ling Z, Chang K, Yang J, Li L. Multiple bacteria associated with the more dysbiotic genitourinary microbiomes in patients with type 2 diabetes mellitus. Sci Rep 2021;11:1824. [PMID: 33469094 DOI: 10.1038/s41598-021-81507-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
469 Anand AC. Nutrition and Muscle in Cirrhosis. J Clin Exp Hepatol. 2017;7:340-357. [PMID: 29234200 DOI: 10.1016/j.jceh.2017.11.001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 10.8] [Reference Citation Analysis]
470 Szabo G, Petrasek J. Gut-liver axis and sterile signals in the development of alcoholic liver disease. Alcohol Alcohol 2017;52:414-24. [PMID: 28482064 DOI: 10.1093/alcalc/agx025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
471 Mehta R, Kabrawala M, Nandwani S, Kalra P, Patel C, Desai P, Parekh K. Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy—A case series. Indian J Gastroenterol 2018;37:559-62. [DOI: 10.1007/s12664-018-0906-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
472 Panyod S, Wu WK, Lu KH, Liu CT, Chu YL, Ho CT, Hsiao WW, Lai YS, Chen WC, Lin YE, Lin SH, Wu MS, Sheen LY. Allicin Modifies the Composition and Function of the Gut Microbiota in Alcoholic Hepatic Steatosis Mice. J Agric Food Chem 2020;68:3088-98. [PMID: 32050766 DOI: 10.1021/acs.jafc.9b07555] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
473 Lee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S, Kang H, Park JH, Kim JH, Lee DH, Lee S, Kim W, Ko G. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun 2020;11:4982. [PMID: 33020474 DOI: 10.1038/s41467-020-18754-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
474 Jain T, Sharma P, Are AC, Vickers SM, Dudeja V. New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries. Front Immunol 2021;12:622064. [PMID: 33708214 DOI: 10.3389/fimmu.2021.622064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
475 Bajaj JS, Acharya C, Fagan A, White MB, Gavis E, Heuman DM, Hylemon PB, Fuchs M, Puri P, Schubert ML, Sanyal AJ, Sterling RK, Stravitz TR, Siddiqui MS, Luketic V, Lee H, Sikaroodi M, Gillevet PM. Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. Am J Gastroenterol. 2018;113:1177-1186. [PMID: 29872220 DOI: 10.1038/s41395-018-0085-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 14.5] [Reference Citation Analysis]
476 Perlemuter G. Circulating bugs in blood in alcoholic liver disease! Hepatology 2018;67:1207-9. [PMID: 29083499 DOI: 10.1002/hep.29624] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
477 Victor DW 3rd, Quigley EM. Microbial therapy in liver disease: probiotics probe the microbiome-gut-liver-brain axis. Gastroenterology 2014;147:1216-8. [PMID: 25457846 DOI: 10.1053/j.gastro.2014.10.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
478 Ponziani FR, Nicoletti A, Gasbarrini A, Pompili M. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1758835919848184. [PMID: 31205505 DOI: 10.1177/1758835919848184] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
479 Wu YF, Lee WF, Salamanca E, Yao WL, Su JN, Wang SY, Hu CJ, Chang WJ. Oral Microbiota Changes in Elderly Patients, an Indicator of Alzheimer's Disease. Int J Environ Res Public Health 2021;18:4211. [PMID: 33921182 DOI: 10.3390/ijerph18084211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
480 Shao JW, Ge TT, Chen SZ, Wang G, Yang Q, Huang CH, Xu LC, Chen Z. Role of bile acids in liver diseases mediated by the gut microbiome. World J Gastroenterol 2021; 27(22): 3010-3021 [PMID: 34168404 DOI: 10.3748/wjg.v27.i22.3010] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
481 Weil D, Pais de Barros JP, Mourey G, Laheurte C, Cypriani B, Badet N, Delabrousse E, Grandclément E, Di Martino V, Saas P, Lagrost L, Thévenot T. Circulating levels of 3-hydroxymyristate, a direct quantification of endotoxaemia in noninfected cirrhotic patients. Liver Int 2019;39:106-14. [PMID: 29931819 DOI: 10.1111/liv.13916] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]